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Abstract 
 
REPRESENTATIVENESS OF PATIENTS ENROLLED IN A PRIMARY CARE 
CLINICAL TRIAL FOR SUBSTANCE USE DISORDERS 
 
By Sydney S. Kelpin, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2016 
Director: Dace S. Svikis, Ph.D., Professor, Department of Psychology 
 
 
Understanding the characteristics of research participants is crucial to ensuring sample 
representativeness and generalizability of findings to broader patient groups with 
substance use disorders. Using anonymous computer-administered health survey data, the 
present study had a unique opportunity to compare patients who chose to participate in an 
RCT for heavy/problem drinking or drug use (N=713; consenters) with those that chose 
not to participate (N=625; non-consenters). The sample was 40% male, 76% African 
American, and had a mean age of 45.2 years. Using multivariate regression, the most 
parsimonious model found older age, unemployment, prescription misuse, positive screen 
for drug problems (CAGE), having a grandmother with an alcohol problem, trouble 
falling asleep (past 30 days), health professional recommendation to go on a diet, and 
feeling unsafe due to a previous partner were all associated with consenting to participate. 
The present study provides benchmark data on sample representativeness in a clinical 
trial of SBIRT. 
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Representativeness of Patients Enrolled in a Primary Care Clinical Trial for Substance 
Use Disorders 
Introduction 
Randomized clinical trials (RCTs) are widely regarded as the gold standard for 
evaluating the efficacy of a treatment for a particular disorder. However, the conclusions 
drawn from an RCT are applicable in clinical settings only to the extent that the trial 
participants resemble the patient population of interest (Humphreys et al., 2013). 
Findings from RCTs with participants who meet rigorous criteria may not generalize to 
those with comorbid psychological disorders, substance abuse, or are homeless. This has 
been a long standing issue in clinical research, beginning first with the 
underrepresentation of women and minorities, resulting in treatment protocols skewed 
toward a norm of middle-aged, white males. The passing of the National Institutes of 
Heath (NIH) Revitalization Act in 1993 served as the first step to address this issue by 
establishing guidelines for the inclusion of women and minorities in clinical research. 
Their inclusion was required except in situations where it would be inappropriate due to 
their health, the purpose of the research, or other circumstances pending NIH approval.   
While this movement improved the representation of these groups, the 
“disconnect” between research and practice was still apparent, particularly in the field of 
substance abuse (Carroll & Rounsaville, 2003). Research has established that large 
proportions of individuals with substance use disorders cannot meet eligibility criteria for 
clinical trials and trial participants have also been found to be markedly different from 
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both community samples and treatment seekers (Humphreys et al., 2013). For example, 
the median clinical trial in the tobacco-dependence field has 12 exclusion criteria and 
approximately two thirds of smokers in the general population are ineligible under one or 
more of such criteria (Le Strat et al., 2011). Similarly for alcohol dependence, 79% of 
treatment-seeking individuals would be ineligible under at least one prevalent clinical 
trial criterion (Blanco et al., 2008), and African Americans are particularly 
underrepresented in such trials (Humphreys and Weisner, 2000; Humphreys et al., 2007). 
Since the 1970’s, treatment outcome studies have become increasingly restrictive in their 
enrollment procedures (Humphreys et al., 2005). Participants in pharmacological and 
psychosocial treatments for substance dependence are fundamentally different from 
individuals receiving care for those disorders in real world treatment facilities 
(Humphreys et al., 2013). Moreover, this research is restricted to only those individuals 
who present for substance abuse treatment, which represents only 15% of individuals 
with a substance user disorder, leaving 85% of the population unstudied (Carroll et al., 
2011; Institute of Medicine, 1990).   
To access this larger patient population that does not present at specialty care 
clinics, intervention efforts have expanded to include medical care settings (e.g., 
emergency departments, primary care clinics) where such persons can be found (Bien et 
al., 1993). In this arena, clinical trials of brief interventions of as little as 15 minutes have 
been shown to be effective with reducing alcohol and other drug use (Bien et al., 1993; 
Hettema et al., 2005). Brief interventions aim to increase patient motivation to make 
positive behavior changes and typically consist of a healthcare professional providing 
assessment, feedback, information, advice, and self-help materials (Beich et al., 2002). 
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Brief interventions have similar efficacy to longer and more intensive interventions 
(Moyer et al., 2002; Burke et al., 2003), and not only produce short-term behavior 
change, but also longer-term, sustained reductions in risk behaviors (Fleming et al., 
1997). Such interventions offer an exciting, new treatment approach, filling the gap 
between primary prevention and more intensive treatment services in a substance abuse 
group not served by existing community and hospital-based substance abuse treatment 
programs.  
Historically, the effectiveness of brief interventions prompted the Institute of 
Medicine to recommend integrating service systems that link community-based screening 
and brief intervention services to assessment and referral activities, resulting in the 
development of a public health approach to substance abuse treatment know as screening, 
brief intervention, and referral to treatment (SBIRT) (Agerwala et al., 2012). SBIRT is an 
evidence-based practice that can be flexibly applied to a range of clinical care settings, 
providing the opportunity for early intervention with at-risk substance users, brief 
treatment for those with less severe SUDs, or referrals to specialized substance abuse 
treatment programs for those with higher severity (Agerwala et al., 2012). While SBIRT 
provides better access to a broader, more heterogeneous patient population, the same 
issues that impact RCTs in substance abuse treatment settings might also influence brief 
interventions research because not all such patients are willing to participate in clinical 
trials. This could decrease sample representativeness and investigator ability to generalize 
study findings.   
Research on the factors associated with participation and nonparticipation in 
SBIRT trials is scarce. In part, this is because it is often difficult to even determine actual 
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rates of participation because researchers seldom report data on the size of the potential 
pool of subjects or the number willing to participate. Understanding the characteristics of 
research participants is crucial to better understand sample representativeness and 
generalizability of findings to broader patient groups with substance use disorders.  
 The purpose of the proposed study is to identify demographic and psychosocial 
variables associated with participation in a large primary care RCT of SBIRT for 
heavy/problem alcohol and/or drug use. The study utilizes screening data from a 4-arm 
RCT, which compared substance use outcomes at 1, 3, and 6 months post-intervention. 
The 4 treatment groups were: screening only (standard care control), assessment only, 
assessment plus computer-delivered brief intervention, and assessment plus therapist-
delivered brief intervention. Participants were identified using a computer-administered 
anonymous health survey with embedded questions about alcohol and other drug use.   
Data was collected on a diverse range of variables including patient demographics, drug 
and alcohol use, family history of substance use, living environment and social supports. 
Using the health survey data from the N=1,338 individuals who met RCT criteria for 
heavy/problem substance use, the proposed study will compare individuals who enrolled 
in the study (N=713; consenters) to those who chose not to participate (N=625; non-
consenters). Based on the RCT literature, the study will test the following hypotheses: 1) 
Non-white ethnic minorities will be less likely to participate compared to white 
individuals. 2) Individuals of lower socioeconomic status will be less likely to participate 
compared to those of a higher socioeconomic status. In addition, given the paucity of 
research on characteristics associated with research participation in similar settings, 
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univariate logistic regression will be used to identify other correlates of RCT study 
participation. 
Review of the Literature 
Brief History 
National Institutes of Health 
 Inclusion of women and minorities in research is necessary in order to make valid 
inferences about health and disease across gender and minority groups (Bennett, 1993).   
Failure to include sufficiently diverse populations in trials leads to treatment protocols 
skewed toward a norm of middle-aged, white males. However, women and members of 
minority groups have historically been excluded from or underrepresented in clinical 
trials. To address this issue, Congress mandated that the National Institutes of Health 
(NIH) ensure that all federally funded clinical research include a valid analysis of 
treatment effects across gender and ethnic groups.  
On June 10, 1993, President Bill Clinton signed into law the NIH Revitalization 
Act, which established guidelines for inclusion of women and minorities in clinical 
research (Freedman et al., 1995). Their inclusion was required except in situations where 
it would be inappropriate due to their health, the purpose of the research, or other 
circumstances pending NIH approval. Further, any NIH-funded clinical trial in which 
women or minority groups were included was required to provide a valid and thorough 
analysis of whether the intervention under study affected women or members of minority 
groups differently from other subjects in the trial. This NIH Act served as a major 
impetus for greater diversity and more representative research samples with findings 
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likely to have greater generalizability than previous research with more narrow and 
restricted samples.  
 Despites these laudable goals, the implementation of the NIH Revitalization Act 
also contributed to both scientific and practical concerns (Woolson et al., 1995). First, the 
Act failed to define “appropriate representation,” leading to a wide array of 
interpretations based on the location of the study and the available population. For 
example, some trials are located in geographic locations in which the area served is 
relatively homogenous with regard to race/ethnicity. These investigators may be 
restricted in what representation they are able to achieve and may only be able to follow 
the guidelines of the Act by recruiting additional sites to increase the population mix. 
While such a strategy may be possible for a multicenter clinical trial, it may not be 
possible for a single-site investigation. Second, a clinical trial must balance the 
conflicting desires for homogeneity and heterogeneity (Bennett, 1993). In the ideal study, 
a cohort is homogenous enough to yield a high probability of learning whether a therapy 
is safe and effective, but also heterogeneous enough to ensure that the observed results 
are applicable beyond a narrowly defined subgroup. Maintaining this balance, while also 
achieving the “appropriate representation” mandated by the Act has been difficult for 
many researchers to achieve. Lastly, subgroup analyses, while conceptually important, 
are often impractical as the clinical trials are often underpowered to examine treatment 
effects within demographic subgroups. As a result, investigators must be cautious when 
interpreting differences in therapeutic response across gender or ethnic groups based on 
small sample sizes. 
CONSORT Statement 
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 In addition to the efforts to improve the representativeness of clinical research, 
strides were also being taken to improve the quality of both the methodology and 
reporting in clinical trials (Moher et al., 2001). The findings from randomized controlled 
trials (RCT) provide valuable information to clinicians and can directly influence patient 
care. Consumers of this research need to understand the design, methods, analysis, and 
generalizability of the trial in order to make informed judgments regarding the internal 
and external validity of the trial. This level of understanding is only possible with 
complete transparency from the authors. In the mid-1990s, an international group of 
clinical researchers, statisticians, epidemiologists, and biomedical editors published the 
Consolidated Standards of Reporting Trials (CONSORT) statement to help researchers 
improve the reporting of their study by use of a checklist and flow diagram (Begg et al., 
1996).   
The CONSORT statement provides guidance for all randomized clinical trials 
(RCT), but focuses on the 2-group parallel-design, as it is the type of trial most 
commonly reported (Moher et al., 2001). The checklist provides a list of 25 items to 
include in the methods, results, and discussion of an RCT report and identifies key pieces 
of information necessary to evaluate the internal and external validity of the study. The 
flow diagram provides information about how to present the progress of participants 
through each phase of the trial. It also provides valuable information about the original 
size of the sample, the number excluded from the study, attrition rates, the number of 
participants in each intervention group and whether the authors conducted an intention-
to-treat analysis. These guidelines were intended to aid in the writing, reviewing, and 
assessing of reports on RCTs. The CONSORT statement received a great deal of support 
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following its publication and was adopted by a number of journals as criteria for 
publication. The CONSORT statement is an iterative document that has continually 
evolved with advances in research. The quality of reporting improved significantly with 
the adoption of the CONSORT guidelines.   
Efficacy Versus Effectiveness  
Despite these advances in clinical research, there was a disconnect between 
research and practice, which was particularly apparent in the treatment of drug abuse 
(Carroll & Rousaville, 2003). It became evident in the early 1980s that there was a lack 
of overlap between the interventions for alcohol dependence that had demonstrated 
efficacy and those routinely being used in alcohol treatment programs (Donovan et al., 
2011). Similarly, very few empirically tested behavioral treatments for drug dependence 
were being used in substance abuse treatment programs, with many such programs using 
interventions that lacked empirical validation. This “gap” in the substance abuse field 
reflected a disconnect between clinical research, efficacy trials conducted primarily in 
academic centers, and the providers, who delivered the majority of treatments in 
community-based drug abuse treatment programs (Tai et al., 2011). Recognition of this 
disconnect introduced the push and pull between two approaches to clinical research: 
efficacy and effectiveness trials. 
Efficacy trials are designed to maximize internal validity by randomly assigning 
patients to a new intervention or treatment, as well as a control condition intended to 
control for professional attention and other nonspecific elements of treatment. The setting 
of the trial, typically a research clinic, is also carefully controlled with an often artificial 
representation of community-based treatment settings. In contrast, effectiveness trials are 
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designed to maximize external validity by recruiting representative samples of patients 
from the community in order to generalize findings to the population of interest.   
Table 1 summarizes the key characteristics of efficacy and effectiveness trials using the 
RE-AIM evaluation framework (Glawgow et al., 2003). Reach refers to the research 
participants and the representativeness of the obtained sample; efficacy or effectiveness 
pertains to the impact of an intervention on the particular outcome of interest; adoption 
refers to the organizations or settings that will conduct the given intervention under 
evaluation; implementation refers to the quality and consistency of the intervention; and 
maintenance refers to the extent to which the treatment becomes institutionalized in an 
organization following its evaluation. 
Table 1. 
 
Efficacy and Effectiveness Research Using RE-AIM Evaluation Framework  
 
RE-AIM Issue Efficacy Studies Effectiveness Studies 
Reach Homogenous, highly 
motivated sample; exclude 
those with complications, 
other comorbid problems 
Broad, heterogeneous, 
representative sample; often 
use a define population 
Efficacy or 
effectiveness 
Intensive specialized 
interventions that attempt to 
maximize effect size; very 
standardized; randomized 
designs 
Brief, feasible interventions 
not requiring great expertise; 
adaptable to setting, 
randomized, time series, or 
quasi-experimental designs  
Adoption Usually 1 setting to reduce 
variability; settings with 
many resources and expert 
staff 
Appeal to and work in 
multiple settings; able to be 
adapted to fit setting 
Implementation Implemented by research 
staff closely following 
specific protocol  
Implemented by variety of 
different staff with competing 
demands, using adapted 
protocol  
Maintenance and cost Few or no issues; focus on 
individual level 
Major issues; setting-level 
maintenance is as important 
as individual-level 
maintenance 
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 The disconnect between research and practice occurs for two primary reasons: 
subject selection and how settings and contextual factors are treated (Glasgow et al., 
2003). In a tightly controlled efficacy trial, only highly motivated, homogenous self-
selected volunteers who do not have any complications or other comorbid conditions are 
eligible to participate. Following the study, the intervention is expected to translate to 
practice and be effective in a much more heterogeneous patient population, many of 
whom have comorbid conditions and may not volunteer for treatment. Secondly, efficacy 
studies typically control variance by restricting the setting to one set of circumstances 
(e.g., one particular clinic), while effectiveness studies attempt to understand the 
variation in outcomes across heterogeneous settings and delivery agents. Thus, 
interventions that are efficacious under highly specific conditions often fail to replicate 
across settings, conditions, and intervention agents in effectiveness research. 
Clinical Trials Network 
Development of CTN 
In an effort to address this disconnect, the National Institute on Drug Abuse 
(NIDA) and the Substance Abuse and Mental Health Services Administration 
(SAMHSA) jointly commissioned the Institute of Medicine (IOM) in 1997 to determine 
means by which interventions developed in academic settings could be translated more 
effectively into clinical practice (Tai et al., 2010). The IOM committee’s report, 
“Bridging the gap between practice and research: Forging partnerships with community-
based drug and alcohol treatment,” provided recommendations to increase 
communication, interaction, and shared involvement of researchers and community-based 
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practitioners in both the development and implementation of interventions. Following 
these recommendations, NIDA established the National Drug Abuse Treatment Clinical 
Trials Network (CTN), whose mission was to improve the translation of science-based 
addiction treatments into community-based practice. 
The CTN brought together academic researchers and community-based providers 
to develop and implement provider-informed clinical trials to be conducted in 
community-based drug treatment settings (Donovan et al., 2011). The partnership 
provided a reciprocal relationship where the researchers were able to address practice-
relevant questions, while also fulfilling the practical needs of community-based treatment 
programs (CTPs). During the first decade of CTN research, the network supported 17 
regional centers and the directors and clinical staff of affiliated community-based 
treatment programs (CTPs). The CTN Steering Committee served as the CTN’s 
governing body to ensure consensus on central research and operational issues.  
Researchers and providers had equal representation with one principal investigator and 
one provider voting from each regional node. The infrastructure of the CTN fostered 
collaboration between researchers and treatment providers to both generate scientific 
findings and more directly inform clinical practice (Tai et al., 2010).   
Bidirectional Partnerships 
 The bidirectional communication and collaboration within the CTN has resulted 
in study designs that meet the needs of both academic and clinical settings, increasing the 
likelihood that treatment providers will make use of research findings (Tai et al., 2010). 
Academic investigators trained to focus on scientific innovation and the validity of 
research methodology partner with providers focused on the quality of patient care, the 
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constraints of clinical budgets, and the challenges of implementing evidence-based 
treatments in clinical practice. This partnership can be challenging, often with conflicting 
views, but ultimately results in research innovation. The promise of this approach was 
evident in the first wave of CTN trials testing brief, simple-to-implement interventions 
including: 1) short-term buprenorphine/naloxone-aided opioid detoxification, 2) one-
session Motivational Interviewing and three-session Motivational Enhancement 
therapies, and 3) low-cost contingency management programs. Efficacy trials of these 
treatments had demonstrated strong evidence for their utility, however these novel 
treatments faced resistance in acceptance and adoption in clinical practice that could be 
addressed with the CTN approach.   
First, providers were reluctant to use pharmacotherapies in the treatment of 
addiction, so despite the evidence for buprenorphine, it was rarely used in practice 
(Saxon & McCarty, 2005). CTN trials had researchers at each Node work closely with 
staff at community treatment programs throughout protocol development and 
implementation to address important research and clinical questions. This collaborative 
approach demonstrated that treatment programs could use buprenorphine safely and 
effectively, creating early adopters that continued to use the buprenorphine in their 
clinical practice after the trial was completed. Second, there was a strong body of 
evidence supporting the use of motivational interviewing interventions (Martins & 
McNeil, 2009), however treatment providers reported that they could not be reimbursed 
for three individual sessions, decreasing its adoption in clinical practice. Thus, the CTN 
conducted two separate trials evaluating a one-session motivational interviewing 
intervention and a three-session motivational enhancement therapy intervention (Carroll 
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et al., 2002). Both trials demonstrated that enhanced motivation improved treatment 
retention, and more importantly, the importance of clinical supervision in ensuring 
effective treatment delivery (Ball et al., 2007; Carroll et al., 2006). This literature 
promoted the recognition and acceptance of rigorous MI training and supervision in the 
field. Lastly, the efficacy of motivational incentives (contingency management) in the 
treatment of substance use disorders had been well established in opioid, marijuana, 
alcohol, cocaine and methamphetamine dependent patients (Bickel et al., 1997; Budney 
et al., 2000; Higgins et al., 2002; Knapp et al., 2007; Petry et al., 2000). However, 
motivational incentives were not adopted by substance abuse treatment providers due to 
concerns about the potential negative consequences of providing tangible reinforcements 
to patients with substance use disorders and the associated costs of offering incentives in 
clinics with limited budgets (Kellogg et al., 2005; Higgins et al., 2008). In an effort to 
overcome these barriers to adoption, the CTN developed two clinical trials testing low-
cost motivational incentive interventions. The findings from these trials and the cost-
effectiveness analyses demonstrated the feasibility and clinical utility of this intervention. 
Similar to the CTN buprenorphine clinical trials, participating treatment providers 
promoted the wider use of motivational incentives following the clinical trials. These 
seminal studies demonstrated that collaboration between researchers and treatment 
providers generated scientific findings that translated to clinical practice. 
Representativeness 
 Consistent with this overarching goal of linking research and practice, the CTN 
also aimed to conduct clinical trials among more diverse samples of substance users than 
may be typical of efficacy trials (Carroll et al., 2002). CTN protocols have aimed to 
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minimize barriers to treatment entry and broaden study inclusion/exclusion criteria in 
order to attract highly heterogeneous samples. For example, many CTN trials limited 
study inclusion criteria to age (18 years or older) and seeking outpatient treatment for a 
substance use disorder.  In these RCTs, participants would be excluded only if they 
required medical detoxification or were psychiatrically or medically unstable to the point 
that outpatient treatment was not feasible. CTN trials have been open to a wide variety of 
substance users with a wide range of co-occurring psychiatric, legal, employment, and 
social problems, better reflecting the 15% of persons with substance use disorders who 
enter specialty care. 
 The multisite approach of the CTN also facilitated obtaining more heterogeneous 
samples by recruiting across clinics to access a diverse patient population (Covey et al., 
2011). The multisite method facilitates faster recruitment, increases study enrollment, and 
achieves better variability in the characteristics of study participants.  Further, the patient 
populations of different sites can be assessed to obtain samples that would not be possible 
with a single site trial (Burlew et al., 2011). For example, certain community treatment 
programs (CTPs) serve higher rates of ethnic minorities and would enable the trial to 
obtain a more representative sample. These sites would be advantageous in that they 
could recruit from their natural caseloads and also have more experience working with 
ethnic minorities. Single site trials with lower rates of ethnic minorities in their caseloads 
are forced to recruit outside of their enrollment streams, which is difficult not only 
logistically, but also often requires further training of clinical staff to be effective with 
populations outside of their usual scope of expertise. 
Recruitment  
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In addition to the representativeness of clinical trials, particular attention also 
started to focus on the method through which participants were obtained. Research 
indicated that there can be significant differences in sample characteristics as a function 
of recruitment method in clinical trials of smokers (Harris et al., 2003), depressed elderly 
patients (Stack et al., 1995), and Alzheimer’s disease patients (Andersen et al., 2010). 
Smokers recruited with reactive methods (disseminating information that asked people to 
call a study hotline) reported significantly higher levels of education and income, better 
health, and significantly lower indicators of depression and life hassles, compared with 
those recruited with proactive methods (in-person appeals by research staff and health 
care providers) (Harris et al., 2003). In depressed elderly patients, referred patients 
included a higher proportion of African Americans and had a lower level of education, 
fewer economic resources, and higher chronic medical burden (Stack et al., 1995). 
Patients recruited with proactive methods had been in their depressive episode longer 
than referred patients at the time of study entry and were 3.4 time more likely to have 
experienced a severe trauma during the 6 months that preceded the onset of their 
depressive symptoms. Lastly, Alzheimer’s patients recruited with reactive methods (e.g., 
mail) were younger and more self-reliant male patients with a higher MMSE sum score, 
while older women with more severe cognitive impairment were recruited from general 
practice with proactive methods. Taken together, evidence began to support the notion 
that the method in which patients are recruited could influence the characteristics of the 
obtained sample. 
Multiple forms of recruitment are routinely used in effectiveness studies, 
particularly with samples that are difficult to recruit, as is often the case in substance 
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abuse research. A CTN study by Winhusen et al (2012) investigated this concept by 
comparing two recruitment methods used at one site of a multi-site trial evaluating 
Seeking Safety (SS), relative to Women’s Health Education (WHE) for women with co-
occurring PTSD and substance use disorders. Participants recruited through newspaper 
advertising, relative to those from substance abuse clinic intakes, had significantly higher 
levels of baseline drug use and a higher percent met DSM-IV-TR criteria for PTSD. In 
turn, the results suggested that the effectiveness of the intervention was greater for this 
more severe sample relative to those recruited directly from the treatment program. Thus, 
recruitment efforts in clinical research may impact sample composition as well as 
treatment effects. 
Where Are We Now? 
While the CTN is committed to bridging the gap between research and practice 
and has made large strides, it is still subject to some concerns. Even if a representative 
sample can be obtained in the CTN, it is still only representative of the population of 
substance users seeking treatment. Only a minority of individuals diagnosed with 
substance use disorders access specialty care (Carroll et al., 2011). Many individuals with 
substance use issues never present at a treatment facility due to a multitude of issues, 
including limited access to care, lack of treatment financing, scarcity of trained clinicians, 
lack of interest in seeking treatment, and stigma. According to SAMHSA’s National 
Survey on Drug Use and Health (NSDUH), 22.7 million persons 12 years and older 
needed treatment for an illicit drug or alcohol use problem in 2013 (SAMHSA, 2013). Of 
these individuals, 2.5 million (11 percent of those who needed treatment) received 
treatment at a specialty facility (i.e. hospital, drug or alcohol rehabilitation or mental 
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health center). Thus, while the CTN created an infrastructure of research partnering with 
community-based treatment centers, this research remains focused only on 15% of 
substance users in the community; namely those who present for treatment.   
Although the generalizability associated with multisite effectiveness trials is 
exciting, the higher levels of heterogeneity in the sample also introduce a variety of 
practical problems (Carroll et al., 2002). Treatment manuals are typically written 
targeting specific types of substance users, however the patient populations across sites 
often vary in disease severity, treatment readiness, treatment resistance, or other 
individual characteristics that could influence treatment response. Additionally, the 
variations among sites can also occur in ways that could obscure outcomes. By only 
assessing aggregate results, specific effects in particular subgroups can be masked. 
Examining site differences and how they may influence the experimental treatment has 
been advocated as a means of ensuring validity and avoiding misrepresentation of 
findings, but it is rarely done in practice. Such challenges, have left investigators with the 
task of setting eligibility criteria broad enough to ensure adequate enrollment of a 
demographically diverse group of patients, while also taking into consideration the costs 
associated with larger samples, and maintaining sufficient power to detect treatment 
effects and readily interpretable results (Humphreys et al., 2007). Thus, despite the 
CTN’s efforts to recruit more representative samples for substance abuse treatment 
research, most of the protocols still sacrifice generalizability for the sake of high internal 
validity (Carroll et al., 2011). 
In turn, the representativeness of this research remains a concern, particularly 
with regard to minorities due to ethnic differences in the factors related to substance use 
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(Burlew et al., 2011). For example, cultural factors result in ethnic differences in drug 
histories (Shillington & Clapp, 2003), specific drugs used (Moselhy & Telfer, 2002), as 
well as overall attitudes about mental health treatment (Buser, 2009).  Further, cultural 
differences in both the spirituality and acculturation to substance use attitudes may also 
influence treatment response. Thus, when certain ethnic groups are underrepresented, it 
impedes the development of effective treatments to reduce health disparities in substance 
use. As of February 2011, the CTN had enrolled 2,700 (22%) African American, 2,071 
(17%) Latino, 179 (1%) American Indian/Alaska Native, 56 (<1%) Asian/Pacific 
Islander, and 1,575 (13%) other/multirace participants across 30 clinical trials. Overall, 
CTN retention rates for ethnic minorities have been similar to the retention rates for 
Whites, however they have varied widely across trials (Burlew et al., 2011). CTN trials 
that included higher rates of ethnic minorities included community treatment programs 
(CTPs) that served a larger proportion of ethnic minorities. CTPs with lower rates of 
ethnic minorities in their caseloads often need to recruit outside their typical enrollment 
streams, making it difficult to obtain a representative sample. Eligibility criteria remain a 
large determinant of investigator ability to recruit ethnic minorities, with the two CTN 
trials having the lowest number of ethnic minorities also listing more stringent eligibility 
criteria. The inclusion criteria from one of these studies required that participants not only 
be using prescription opiates, but also meet criteria for attention-deficit/hyperactivity 
disorder (ADHD) and smoke more than 10 cigarettes per day. Lastly, the two trials with 
the lowest ethnic minority enrollment were medication trials, whereas the trials with the 
higher numbers of ethnic minorities were behavioral trials. This suggests that the type of 
trial may also influence the recruitment of ethnic minorities. 
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Overall, the multisite approach of the CTN has made great strides in clinical 
research and offered the first step toward effectiveness trials in the field of substance 
abuse. However, over the course of the CTN, the aforementioned challenges of 
generalizability, recruitment, and the overall representativeness of this research have 
become a cause for concern. In an effort to address these issues, there may be a tendency 
for CTN sites to be selected for new trials based upon track records of successful (more 
rapid) recruitment in prior research trials rather than for their representativeness of the 
larger population of community-based treatment programs (Nunes et al., 2010). This 
approach is understandable as it ensures the integrity and feasibility of the research.  
However, the selected community-based treatment programs may become more like 
research clinics over time once again listing their representativeness of the target 
population and undermining the original mission of the CTN. Taken together, such 
factors have contributed to the expansion of clinical trials to include new health care 
settings such as primary and specialty medical care with a focus on screening, brief 
intervention, and referral to treatment (SBIRT). 
SBIRT 
Epidemiology of Substance Use Disorders 
 An estimated 24.6 million Americans aged 12 or older report using illicit drugs in 
the past month and 60.1 million report binge drinking over that same time interval 
(SAMHSA, 2013). Only 11% of those in need of treatment received care at a specialty 
facility, and of those not receiving treatment, 96% felt they were not in need of such 
services. Thus, the majority of persons with heavy/problem alcohol or drug use are not 
actively engaged in traditional substance abuse treatment. While the majority of such 
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persons are not likely to seek substance abuse treatment, they are more likely to seek 
medical care for a variety of health problems associated with heavy drug use (Mertens, et 
al., 2003). Research has shown that between 8 and 25% of primary care patients meet 
criteria for heavy/problem substance use (Mertens et al., 2003; Brown et al., 2001; 
Fleming et al., 1997). Taken together, primary care clinics were identified as an ideal 
setting for education and intervention with this at- risk population of heavy/problem 
substance users. 
Overview 
 Screening, brief intervention, and referral to treatment (SBIRT) is an evidence-
based practice used to identify, reduce, and prevent problematic substance use (Agerwala 
& McCance-Katz, 2012). SBIRT is a public health approach to the delivery of early 
intervention and treatment services that can be applied in a range of clinical care settings 
including hospital emergency settings, primary care centers, office- and clinic-based 
practices, and other community based centers, providing access to patient populations 
that may not present in traditional treatment facilities. SBIRT interventions can provide 
brief treatment for those with less severe SUDs or referrals to specialized care for those 
with more severe substance use. 
SBIRT is comprised of three stages: screening, brief intervention, and referral to 
treatment (Agerwala & McCance-Katz, 2012). Screening involves a brief assessment to 
evaluate current severity of substance use and identifies the appropriate level of 
treatment. For patients who screen positive for problem or risky substance use, screening 
is followed by brief intervention with a focus on preventing the progression to a full-
blown SUD. Brief interventions refer to any time-limited effort, typically 1-2 brief 
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conversations, to increase patient awareness regarding their substance use and motivation 
toward behavioral change. Referral to treatment facilitates access to care for patients 
identified as already having a substance-related health condition or a suspected use 
disorder that warrants a formal diagnosis and requires specialty treatment. 
History of SBIRT 
The current model of SBIRT began in the 1980s as reliable screening tools, such 
as the Michigan Alcohol Screening Test (Selzer, 1971), the CAGE (Ewing, 1984), and 
the Drug Abuse Screening Test (Skinner, 1982) became available (see Babor & Kadden, 
2005 for review). These tools were required in order to provide rapid methods of 
universal screening for substance use. The development of such screening tools 
facilitated the integration of substance abuse treatment services into primary care settings 
due to the new ability to identify patients in need of such services. The impetus for the 
integration of substance abuse services into primary care grew from findings that patients 
who received encouragement from their health care providers to cut down or stop 
drinking had lower levels of alcohol consumption and decreased mortality associated 
with heavy drinking compared to controls who were informed by letter to be restrictive 
with their alcohol consumption (Kristenson et al., 1983). Similarly, brief physician advice 
was found to significantly help patients stop smoking cigarettes compared to usual care 
controls (Russell, Stapleton & Hajek, 1988). 
The goal of brief interventions is to increase patient motivation to make positive 
behavior changes. Brief interventions typically consist of six elements summarized by the 
acronym FRAMES: Feedback, Responsibility, Advice, Menu, Empathy, and Self-
efficacy (Miller & Sanchez, 1994). The health care provider provides feedback on the 
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patient’s current substance use, advises on how to quit or cut down, offers a menu of 
options for change, and supports the patient’s self-efficacy to enact those changes. Brief 
interventions were shown to be similar in efficacy to longer and more intensive 
interventions (Moyer et al., 2002; Burke et al., 2003), and were associated with not only 
short-term but also longer-term behavior change, with sustained reductions in risk 
behaviors (Fleming et al., 1997). Brief interventions of as little as 15 minutes were shown 
to be effective with reductions in alcohol and other drug use (Bien et al., 1993; Hettema 
et al., 2005). They offered an exciting, new treatment approach that filled the gap 
between primary prevention and more intensive treatment services by identifying patients 
that may never present for specialty care. Recognizing the potential of SBIRT from these 
seminal studies, the World Health Organization (WHO) focused on how to best 
implement screening and brief intervention in primary care settings, and more broadly, 
how to integrate SBIRT into health care systems around the world (Agerwala & 
McCance-Katz, 2012). 
Such efforts began in emergency departments (ED), which serve as the safety net 
of care in the United States, and as a result, become the point of access to health care for 
millions of Americans (Bernstein et al., 2009). In 2011, approximately 2.5 million ED 
visits were related to drug misuse or abuse (Drug Abuse Warning Network, 2011). 
Understanding that a visit may appear in more than one group, approximately 51 percent 
of these visits involved illicit drugs, 51 percent involved nonmedical use of 
pharmaceuticals, and 25 percent involved drugs combined with alcohol. Thus, the ED is a 
primary setting to access substance users that otherwise might not present for treatment.  
Further, patients with substance use and mental health conditions visit the ED with 
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greater frequency compared to patients without these disorders (Bernstein et al., 2009). 
This data, combined with the findings of research in the CTN, prompted further 
expansion of the SBIRT intervention into numerous primary care settings, and has 
become the standard of care in recent years. 
Affordable Care Act 
 Implementation of SBIRT in primary care settings comes at a pivotal time in 
health care reform. Historically, public substance abuse treatment services have operated 
independent of the overall health care system, utilizing separate administration, funding, 
and service delivery systems (Buck, 2011). The 2009 National Survey on Drug and 
Health reported that respondents in inpatient treatment for alcohol or drug problems in 
the US population age twelve and older were 50 percent more likely to identify a 
rehabilitation facility as their source of inpatient care, compared to a hospital (SAMHSA, 
2009). Outpatient care followed the same access pattern with treatment in a rehabilitation 
facility two-and-a-half times more frequent than treatment in a private doctor’s office. 
Most of these specialty clinics are stand-alone nonprofit or government operated facilities 
that carry daily caseloads of fifty or fewer patients (Buck, 2011). More than three-
quarters of the funding for these specialty clinics comes from public sources, compared to 
less than half for all other health care (Levit et al., 2008). Further, staff members who 
have limited professional training and supervision typically deliver the treatment 
(Roman, Ducharme & Knudsen, 2006; Willenbring, 2010; McLellan & Meyers, 2004). 
Less than half of the treatment facilities that rely on public funding employ counselors 
trained at the master’s degree level and a third do not have a physician either on staff or 
contract. The Affordable Care Act of 2010, coupled with declines in state general 
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revenue spending, marked the beginning of systemic change in the financing, structure, 
and delivery of substance abuse treatment services.   
 The Affordable Care Act includes several provisions that affect substance abuse 
treatment services, most notably; the law greatly expanded the number of insured people 
with substance abuse disorders (Buck, 2011). A provision within the law mandates that 
people who meet 133 percent of the federal poverty level are eligible to receive 
Medicaid. This expansion was estimated to nearly double the number of nonelderly 
childless adults with behavioral health disorders in Medicaid, because this population is 
primarily low-income and uninsured. The majority of people with behavioral health 
disorders gaining this coverage are likely to be those with mental health conditions, 
however this provision will likely have the greatest impact for those individuals with 
substance abuse disorders. Medicaid or Medicare eligibility is available for nonelderly 
childless adults with serious mental illness through Supplemental Security Income or 
Social Security Disability, both of which require a determination of disability. However, 
eligibility is typically denied for those with substance use disorders if their drug or 
alcohol abuse is the primary cause of the disability. Under the Affordable Care Act, this 
barrier to insurance coverage will no longer exist, and all individuals whose income 
meets criteria are eligible. 
 The expansion of Medicaid coverage resulted in further medicalization of public 
substance abuse treatment and greater participation from physicians, psychologists, nurse 
practitioners, and other health professionals (Buck, 2011). Medicaid outpatient services 
typically require physician-directed services for reimbursement. Substance abuse 
treatment services that consist primarily of education and psychosocial support provided 
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by peer or lay counselors do not constitute medical assistance and in isolation, may not 
qualify for Medicaid reimbursement. Thus, health centers are uniquely positioned to 
respond to the increased demand for substance abuse treatment, resulting in a shift away 
from residential and stand-alone programs toward integrating these services into the 
mainstream of general health care. Under this health reform, addiction is recognized as a 
chronic relapsing disorder that should be treated in primary care, providing patients with 
better access to substance abuse services that are medically based and person-centered.  
More patients will be presenting in primary care to receive substance abuse treatment, 
providing easier access to this patient population for both treatment and research efforts. 
Who Participates? 
As substance abuse research expands to the primary care setting, it provides 
access to the 85% of patients that do not seek treatment. While in many ways access to 
this population seems to increase generalizability, the fact is we do not know how many 
of them will consent to research participation, and how, if at all, those consenting may 
differ from the population of interest. Although the CONSORT statement promotes better 
tracking of participants, the majority of studies are not reporting the characteristics of 
participants that are eligible for the trial but do not elect to participate, which is important 
information to consider when interpreting the findings, as well as when translating 
research to clinical practice. For example, a study conducted by Berstein et al. (2011), 
investigating the efficacy of a brief smoking cessation intervention among emergency 
department patients, had 663 patients eligible to participate of whom N=325 declined. 
The study included a consort diagram listing the reasons for declining to participate 
including: refused to participate, admitted, not interested in quitting or already quit, and 
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other. Although this is important information to include, it does not provide any insight 
into patient demographics and how they may differ from the sample under investigation. 
This is nearly half of the eligible participant pool that was excluded from analyses. This 
information is particularly important now that substance abuse services are being 
integrated in primary care. In specialty care, everyone presenting for treatment has a 
substance related issue, however in primary care, understanding the larger pool of eligible 
participants begins with screening and only a subset go on to participate in the trial. This 
information enables better understanding of patients’ reasons for declining research 
participation (e.g., stigma) and the characteristics that may influence those reasons (e.g., 
demographics, substance use severity).  
There are many factors that can contribute to nonparticipation in clinical trials 
including, the treatment options not being of interest, lack of time, research burden being 
too great, lack of transportation and/or child care. However, there may be additional 
factors at play in substance abuse research due to the strict regulations, fear of legal 
consequences, and stigma associated with substance use (Andreae et al., 2016). Stigma 
surrounding certain behaviors (e.g., substance use during pregnancy) and groups (e.g., 
injection drug users) are widely accepted, culturally endorsed and supported by criminal 
law (Livingston et al., 2012). The stigma surrounding substance use is also unique in that 
people with this condition are often perceived as having personal control over their 
illness, and thus more likely to be held responsible and blamed (Schomerus et al., 2011; 
Albrecht, Walker & Levy, 1982; Corrigan, Kuwabara & O’Shaughnessy, 2009). Stigma 
has been well established as a significant barrier for accessing health care and substance 
use treatment services (Radcliffe & Stevens, 2008; Copeland, 1997; Digiusto & Treloar, 
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2007; Keyes et al., 2010; Semple, Grant & Patterson, 2005). Health-care providers may 
hold negative beliefs about people with substance use disorders, including that they abuse 
the system with drug seeking behavior, overuse system resources, are not vested in their 
own health, and fail to adhere to doctor recommendations (Mak et al., 2007; Henderson, 
Stacy & Dohan, 2008). Thus, individuals with substance use disorders may conceal their 
use in order to avoid this stigma. There have not been any studies on the role of stigma in 
SBIRT research, however the fact that the substance users presenting in primary care are 
the 85% not seeking treatment for their substance use, it is likely that stigma may also 
play a role in their willingness to participate in clinical research. Understanding how 
these factors influence research participation is critical in order to tailor research efforts 
to target these populations.  
To date, we found no published studies investigating differences among 
individuals that accept and decline participation in SBIRT research. However, trends in 
research participation have emerged from more general clinical trials in medical based 
settings. Historically, African Americans and other minority populations have 
participated in clinical trials far less when compared to whites, even after the NIH 
Revitalization Act of 1993 (Durant et al., 2011; Anwuri et al., 2013). Racial differences 
in the willingness to participate in medical research have been largely attributed to 
mistrust of researchers and health care providers. Rooted in historical events such as the 
US Public Health Services Syphilis Study at Tuskegee (Tuskegee Study) among African 
Americans and efforts to sterilize American Indians, mistrust has been associated with 
the perception that research will benefit Whites of the research institution and not people 
of color, a fear of purposeful mistreatment, and the perception that by signing the 
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informed consent they are relinquishing their rights and providing the researcher with 
legal protection against any harm that may be inflicted on the participants (George et al., 
2014). Other well-established barriers for minority populations include a lack of 
informational access about research opportunities, a fear of discrimination from health 
insurance companies that may result from participating in health research, and a fear of 
deportation.   
Another factor that has consistently been associated with decreased research 
participation is low socioeconomic status (Unger et al., 2013; Ford et al., 2008; Sateren et 
al., 2002; Guiliano et al., 2000). Regardless of race or ethnicity, low SES (e.g., 
educational attainment, income, employment status, insurance coverage) has consistently 
been shown to have a negative impact on clinical research participation. This has largely 
been attributed to individuals of lower socioeconomic status having limited access to 
health care, resulting in low rates of prevention and diagnostic procedures, and higher 
dependence on public hospitals where physicians are less likely to be involved in clinical 
research (Giuliano et al., 2000). Second, low SES patients are more likely to rely on 
Medicare and Medicaid insurance and coverage of costs associated with participation in a 
clinical trial is inconsistent and often denied. Further, there can be ethnical concerns 
associated with recruiting low SES patients and patients without health insurance because 
if an abnormality or problem is detected, these patients may not have adequate resources 
to receive follow-up care.  
Beyond these characteristics, little is known about what other factors may be 
associated with participation in clinical research. This information provides insight into 
potential differences between individuals that choose to partake in research compared to 
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those that do not, however the screening information is so limited, that in a typical trial, 
little is known beyond the age, gender, race, and level of substance use. Thus, it is 
difficult to gain a complete understanding of how these two groups may differ because 
individuals that choose not to participate are never given a comprehensive screener. 
Sampling 
 Gaining a better understanding of how individuals that agree to participate in 
research differ from those that do not is valuable information because sampling can 
directly influence the outcome of the study. Understanding the characteristics of 
individuals that participate in research is critical to making meaning out of the study 
findings. Interventions can vary in their effectiveness based on the characteristics of the 
sample under investigation. For example, evidence for the efficacy of brief interventions 
for alcohol use disorders on the milder end of the severity spectrum is well established 
(Kaner, et al., 2007; Jonas et al., 2012; D’Onofrio et al., 2012). However, brief 
interventions have been found to be less effective in dependent drinkers who may benefit 
from more specialized and intensive treatment (Bogenshutz et al., 2014; Gentilello et al., 
1999).   
Research findings have also been found to vary as a result of demographic 
characteristics such as gender and age. The overall evidence suggests that brief alcohol 
interventions are equally effective in men and women (Ballesteros et al., 2004; Whitlock 
et al., 2004; Bertholet et al., 2005), however most of the literature to date has focused 
primarily on male drinkers or not reported the data disaggregated by sex (Moyer et al., 
2002; Kaner et al., 2007). Research studies that have included women in their analyses 
have yielded mixed results thus far, suggesting that brief interventions may not be 
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consistently helpful to women (Chang, 2002). Further, although brief interventions for 
alcohol-related disorders appear to be effective in adults aged eighteen and over, the 
findings at either end of the age spectrum are less conclusive. Research conducted 
primarily in US college settings has suggested that the effects of brief interventions are 
less long-lived in young adults, and there is insufficient evidence on BI effectiveness in 
either adolescent (Kaner et al., 2007; Jackson et al., 2010; Latimer et al., 2010) or older 
adult populations (Kaner et al., 2007; Jonas et al., 2012). 
Lastly, little consideration has been given to the influence of socioeconomic status 
on effectiveness of brief interventions (Littlejohn, 2006; Gordon et al., 2007; Jackson al., 
2010), and a number of reviews have noted the tendency for studies to either omit ethnic 
minorities or that they are poorly reported when included, often neither giving the 
breakdown of participants nor analyzing them separately (Gorden et al., 2007; Whitlock 
et al., 2004; Kaner et al., 2007; Jackson et al., 2010; Jonas et al., 2012). There has also 
been a lack of conclusive evidence on the use of brief interventions in patients with co-
morbid medical or psychiatric conditions, as these individuals are typically screened out 
to minimize the heterogeneity of the study sample. Thus, the sample plays a pivotal role 
in the study findings. Research needs to be meaningful to the general population.  
Gaining a better understanding of fundamental differences between individuals that 
participate in research would provide insight into the populations we are studying and 
provide information of value to both researchers and clinicians. 
Statement of the Problem and Hypotheses 
 Randomized clinical trials (RCTs) are widely regarded as the gold standard for 
evaluating the efficacy of treatment for a particular disorder. However, there is still an 
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apparent disconnect between research and practice, particularly in the field of substance 
abuse (Carroll & Rounsaville, 2003). This is due in part to the fact that participants in 
pharmacological and psychosocial treatments for substance dependence are 
fundamentally different from individuals receiving care for those disorders in real world 
treatment facilities due to strict exclusion criteria and limited minority participation 
(Humphrey et al., 2013; Humphreys, 2003; Humphreys et al., 2007). Moreover, this 
research is only targeting the 15% of substance users that actually present for specialty 
care, leaving 85% of the population unstudied (Institute of Medicine, 1990). 
 In an effort to identify and serve this larger patient population that does not 
present for substance abuse treatment, intervention efforts expanded to focus on medical 
care settings (e.g., emergency departments, primary care clinics), such efforts contributed 
to the development of a public health approach to substance abuse treatment: screening, 
brief intervention, and referral to treatment (SBIRT) (Agerwala et al., 2012). Although 
SBIRT provides better access to this patient population, the same issues that impact 
RCTs in substance abuse treatment settings are also likely to influence brief 
interventions. SBIRT provides better access to a broader, more heterogeneous patient 
population, however not all such patients are willing to participate in SBIRT research, 
which might decrease sample representativeness and investigator ability to generalize 
study findings. Research on the factors associated with participation and nonparticipation 
in SBIRT trials is scarce and it is often difficult to even determine actual rates of 
participation because published results often do not report on such data.   
The present study identified demographic and psychosocial variables associated 
with participation in a large primary care RCT of SBIRT targeting heavy/problem alcohol 
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and/or drug use. The study utilized anonymous, computer-administered health survey 
data in which patients who screened positive for heavy/problem substance use were 
randomized to one of four treatment groups: screening only, assessment only, assessment 
plus computer-delivered brief intervention, and assessment plus therapist-delivered brief 
intervention. To our knowledge, there have not been any other studies investigating 
predictors of research participation within this patient population. Based on findings for 
participants enrolled more broadly in clinical trials research, the study tested the 
following hypotheses: 1) Non-white ethnic minorities would be less likely to participate 
compared to white individuals.  2) Individuals of lower socioeconomic status would be 
less likely to participate compared to those of a higher socioeconomic status. In addition, 
given the paucity of research on other characteristics associated with research 
participation in similar settings, univariate logistic regression was used to identify 
additional demographic, clinical and psychosocial correlates of RCT study participation. 
Methods 
Participants 
 Participants were drawn from a data base containing N = 4,552 primary care 
patients who completed an anonymous, computer-delivered health survey. From this 
pool, the present study selected the N=1,338 individuals who met RCT inclusion criteria 
for heavy/problem alcohol and/or other drug use. Specifically, study compared 
individuals who consented to participate in the SBIRT RCT (N=713; consenters) and 
those that chose not to participate (N=625; non-consenters). 
 Inclusion criteria. Adults who were 18 years of age or older, seeking primary 
care at VCUHS, residing within the hospital catchment area (City of Richmond and 
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surrounding counties), able to speak and understand English, indicated they were not 
currently enrolled in alcohol/drug treatment (inpatient, residential, outpatient, methadone 
maintenance, therapeutic community), and who met criteria for heavy/problem alcohol 
and/or drug use were eligible for the RCT. 
 Heavy/problem alcohol use was defined as either: 1) A score greater than or equal 
to 2 on the CAGE (for men) or greater than 2 on the T-ACE (for women) combined with 
self-report of consuming more than 14 drinks/week (men) or 7 drinks/week (women) 
over the past 30 days; or 2) Self-reported consumption of more than 4 drinks (men) or 
more than 3 drinks (women) on at least two occasions in the past 30 days. 
 Heavy/problem drug use was defined in the following 3 ways: 1) A score of 
greater than or equal to 1 on Drug CAGE combined with a report of drug use on at least 
one occasion in the past 30 days; 2) using one or more illicit drugs at least 2 days/week in 
the past 30 days; or 3) using prescribed medications in contraindicated ways (e.g., taking 
more than prescribed, using someone else’s prescription, getting medications from more 
than one health provider) on at least 2 occasions in the past 30 days. 
Exclusion criteria. Patients were ineligible for the RCT if they presented with a 
serious psychiatric or cognitive impairment that prevented them from giving true 
informed consent. 
The study was approved by Virginia Commonwealth University’s Institutional 
Review Board under “Project COMP: A Randomized Clinical Trial, ” protocol number 
HM13196 and all participants provided informed consent. 
Design and Procedures  
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 Participants were recruited from the VCUHS primary care and OB/GYN clinic 
waiting rooms by trained study staff. Potential participants were approached at random in 
the lobby area while they were waiting to see their practitioner. They were asked if they 
were at least 18 years of age, and if they answered yes, RAs proceeded to tell them about 
an anonymous health behavior study (Health Cheq) and asked if they wanted to learn 
more about the study. If yes, the patient was escorted to a private area adjacent to the 
clinic waiting room, where the research assistant briefly told them about the study. 
Specifically, they were told that the study sought to learn more about the health behaviors 
of patients in the VCUHS Primary Care Clinic and OB/GYN Clinic. It was a computer-
directed survey that focused on health behaviors, including sleep, mood, diet and 
exercise, smoking, drinking, and medication/drug use. They were informed that the 
survey would only take 20 minutes and they would receive $10 for their time and effort. 
They were also informed that based on their responses to these questions, they may have 
the opportunity to participate in another study that the research assistant would tell them 
more about, if they were eligible.  
Patients who met inclusion criteria and provided informed consent were taken to a 
quiet area proximal to the waiting room. The research assistant logged them onto a touch-
screen computer and left the area while the patient completed the survey. A mobile three-
dimensional cartoon character (Peedy the Parrot) read each item for the participant, acted 
as narrator, and guided them throughout the process. Participants listened to Peedy via 
headphones to ensure privacy. Upon completion, each participant was given a $10 gift 
card for their time while the computer determined whether the patient met eligibility 
criteria for the SBIRT randomized clinical trial (RCT). Participants who screened 
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positive for heavy/problem substance use were informed that they qualified for the RCT 
and were invited to participate. They were informed that if they chose to participate in the 
RCT the computer would assign them, by chance, to one of four study groups.  
Depending upon the group they were assigned to, the research would take anywhere from 
5 to 40 additional minutes on that day and then they would be scheduled for 20-40 minute 
follow-up research visits 1, 3, and 6 months post enrollment. They were informed that 
regardless of group assignment, they would receive $20 for participating, and could earn 
an additional $120 for completing the three follow-up sessions. They were reminded that 
their answers to survey questions and their participation in the study would be 
confidential. If the participant consented to the RCT, they were randomized to one of the 
four study groups: true control, assessment only, assessment plus computer-delivered 
brief intervention, and assessment plus therapist-delivered brief intervention. If the 
participant was not eligible, they were compensated and thanked for their participation.  
Measures 
 The survey was administered using a laptop computer and participants were 
oriented to the computer and study procedures by the RA. Participants could use either 
the touchscreen or keyboard/mouse to proceed through the survey.  All answers were 
provided by choosing responses from a list or by touching a visual analogue scale.  
Pleasing and relevant graphics changed with each screen to maintain interest. The 
program was completely private and required no computer or reading literacy. 
Participants wore headphones that enabled them to listen to Peedy the Parrot who served 
as narrator and guided them through the Health Cheq survey. Alcohol and drug use items 
to determine RCT eligibility were embedded within the larger Health survey that focused 
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on demographics, general health, mood and anxiety, smoking, nutrition and other health 
behaviors and concerns. This was done to minimize any stigma associated with 
completing a screener about substance use.  
Demographic Characteristics and Health Behaviors. Demographic variables 
included age, race, education, employment, marital status, current living situation, social 
services, and insurance coverage. Items addressing general health behaviors and concerns 
were also included such as exercise, nutrition, diet, as well as computer literacy.  
Smoking Behavior. Quantity and frequency of recent tobacco use were assessed 
with items from the Fagerstom Test for Nicotine Dependence (Heatherton et al., 1991). 
The items assessed a range of current smoking behaviors including the number of 
cigarettes smoked per day, the amount of time after waking in the morning to first 
cigarette, and which cigarette would be the most difficult to give up. The Fagerstrom Test 
for Nicotine Dependence has demonstrated high reliability, as well as validity when using 
cotinine as a criterion variable (Pomerleau et al., 1994). Lifetime tobacco use was 
assessed with items from the National Survey on Drug Use and Health (Wells et al., 
2006). The items quantified lifetime cigarette smoking with questions such as: “Which 
statement best describes your smoking behavior over your lifetime?” with 3 response 
options (1 = 100 or more cigarettes and 3 = I have never smoked cigarettes). The tobacco 
items were the first substance use questions presented to the patients in order to give 
them a chance to get familiar with the software and the program narrator, Peedy the 
Parrot, while reporting on a health behavior that is less socially stigmatizing than 
heavy/problem alcohol or drug use.  
  37 
Physical and Emotional Health. Participants were presented with a range of 
medical conditions related to addiction (e.g., chronic obstructive pulmonary disease 
(COPD), arthritis, hepatitis, liver disease, pancreatitis) and asked whether they had ever 
received a diagnosis for any of the listed conditions. They were also asked about the 
reason for their current medical visit (e.g., yearly check-up, new health problem, ongoing 
health problem) and, in general, how would they rate their overall health on a 5 point 
scale (1 = excellent and 5 = poor). 
Patient Health Questionnaire (PHQ-9). Depressive symptoms were assessed 
using items from the Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer & 
Williams, 2001). The PHQ-9 is a 9-item depression measure, which scores each of the 9 
DSM-IV criteria on a 4-point scale (0 = not at all and 3 = nearly every day). The 
diagnostic validity of the PHQ-9 has been well established in the primary care setting 
with 2 studies involving 3,000 patients in 8 primary care clinics and 3,000 patients in 7 
obstetrics-gynecology clinics (Sptizer et al., 1999; Spitzer et al., 2000). The PHQ-9 is 
half the length of other depression measures, while still maintaining comparable 
sensitivity (88%) and specificity (88%). 
General Anxiety Disorder (GAD-7). Anxiety symptoms were assessed using 
items from the Generalized Anxiety Disorder Screener (GAD-7) (Spitzer et al, 2006). 
The GAD-7 is a 7-item anxiety measure, which scores the 7 core symptoms of 
generalized anxiety disorder on a 4-point scale (0 = not at all and 3 = nearly every day). 
The diagnostic validity of the GAD-7 has been well established in the primary care 
setting with a criterion-standard study performed in 15 primary clinics in the United 
States demonstrating good consistency between GAD-7 diagnosis and those of 
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independent mental health professionals (sensitivity, 89%; specificity, 82%) (Spitzer et 
al, 2006).   
Sleep Behavior. Sleep behavior was assessed using items from the Insomnia 
Severity Index (Bastian, Vallieres & Morin, 2001). Participants were asked to rate if they 
had difficulty falling asleep, staying asleep, or problems waking up too early on a 5 point 
scale (1 = none and 5 = very severe). The Insomnia Severity Index corresponds with the 
DSM-IV criteria for insomnia, and measures perceptions of symptom severity, distress, 
and daytime impairment. The diagnostic validity of the measure has been well 
established in distinguishing individuals diagnosed with primary insomnia from good 
sleeper controls (sensitivity, 94%; specificity 94%) (Smith & Wegener, 2003). The use of 
prescription medications for sleep was also assessed with an item from the Pittsburgh 
Sleep Quality Index (PSQI) asking participants if they took any medication to help them 
sleep in the past 30 days, and if so, how often did they take this medication as a sleep aid 
on a 4 point scale (1 = daily and 4 = less than twice per week) (Buysse et al., 1989). This 
measure has also demonstrated diagnostic validity in distinguishing good and poor 
sleepers (sensitivity, 89.6%; specificity, 86.5%). 
Alcohol Use and Problems. Items were included to assess the quantity and 
frequency of recent use (past 30 days), as well as binge drinking. NIAAA guidelines were 
used to define drinking behaviors, with heavy drinking defined as more than 7 drinks per 
week for women and more than 14 drinks per week for men (NIAAA, 2009). Binge 
drinking corresponded to having more than 4 drinks on a single occasion for women and 
more than 5 drinks on a single occasion for men (NIAAA, 2009).    
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T-ACE. The T-ACE, a brief 4-item questionnaire was used to detect risky 
drinking in women. The T-ACE was developed in 1989 (Sokol, Martier, & Ager) to 
detect alcohol consumption in women that could potentially harm the fetus. The T-ACE, 
a mnemonic that stands for Tolerance, Annoyed, Cut down, and Eye opener, uses 
identical questions for three of the four questions from the CAGE, but replaces the Guilt 
question with a Tolerance (High) question: (How many drinks does it take to make you 
feel high?). Thus, the main difference between the two measures is that the CAGE asks 
whether the patient felt guilty about drinking, while the T-ACE asks how many drinks it 
takes to make the patient feel high (Tolerance). The reason for this difference is that 
Sokol and colleagues (1989) found that the tolerance question, when added to the CAGE, 
showed that all items, with the exclusion of feeling bad or guilty, contributed 
significantly to the indication of risk drinking during pregnancy.  Since the tolerance 
question carried more weight, developers assigned a score of 2 for the tolerance question. 
Thus, two points are assigned when a woman reports needing over two drinks in order to 
feel the intoxicating effects of alcohol or to feel “high.” A score of 1 was assigned for 
each of the ACE questions. Therefore, scores range from 0 to 5. The present study used a 
cut-point of ≥ 2 on the T-ACE to predict risk drinking (Sokol, et al., 1989).   
CAGE. While it can be used for males and females, the present study used the 
alcohol CAGE to detect problem drinking in men (Ewing & Rouse, 1970). CAGE is a 
mnemonic that stands for Cut down, Annoyed, Guilty, and Eye opener, and was 
originally standardized with a sample of White men. The four CAGE questions are: 1) 
Have you ever felt you should Cut down on your drinking?, 2) Have people Annoyed you 
by criticizing your drinking?, 3) Have you ever felt bad or Guilty about your drinking?, 
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and 4) Have you ever had a drink first thing in the morning to steady your nerves or get 
rid of a hangover (Eye opener)? Each affirmative response receives one point with total 
scores ranging from zero to four. A cut-off of ≥ 2 points on the CAGE is used as an 
indication of problem drinking (Mayfield, et al., 1974). CAGE has demonstrated high 
test-retest reliability and adequate correlations (0.48-0.70) with other screening 
instruments (Dhalla & Kopec, 2007). The questionnaire has been well established as a 
valid tool for detecting alcohol abuse in primary care patients (sensitivity, 71%; 
specificity, 91%). 
Recreational/Illicit Use and Problems. Participants were presented with a list of 
various classes of drugs (modified from the CIDI drug module) (Ustun et al., 1997) and 
asked to check which drugs they used regularly (e.g., three or more times per week). The 
list included marijuana, cocaine, stimulants, inhalants, heroin, and hallucinogens. For 
those drugs endorsed, they were asked about their frequency of use in the past 30 days, 
including how many days they used as well as their average use per week.   
Drug CAGE. Other drug use was assessed using the same question format as the 
original CAGE but was adapted to focus on other drug use: 1) Have you ever felt you 
should Cut down on your drug use?, 2) Have people Annoyed you by criticizing your 
drug use?, 3) Have you ever felt bad or Guilty about your drug use?, and 4) Have you 
ever used drugs first thing in the morning (Eye opener)? (Ewing & Rouse, 1970).  Each 
affirmative response receives one point with total scores ranging from zero to four. A cut-
off of ≥ 1 points on the Drug CAGE is used as an indication of substance abuse. 
Prescription Misuse. Participants were asked if they had misused any of their 
medications in the past 30 days, with prescription misuse defined as taking more pills 
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than prescribed, taking pills more often than prescribed, using medication prescribed for 
someone else, or getting the same medication from more than one doctor. Patients were 
asked the frequency of their prescription misuse in the past 30 days, as well as what types 
of medications were misused from the following list: sleeping medicines, sedative 
medicines, stimulant medicines, stimulant medicines, and pain medicines. 
Family History of Alcohol and Drug Problems. Participants were asked to 
report any problem alcohol or drug use of first-degree relatives and grandparents. 
Participants were also asked if they were living with someone who currently has a 
problem with drugs and/or alcohol with options yes/no/I don’t know (McLellan et al., 
1992).  
Partner Violence Screen. The 3-item Partner Violence Screen was included to 
assess two dimensions of partner violence: physical violence and perceived safety 
(Feldhaus et al., 1997). Physical violence was assessed by asking,“ Have you been hit, 
kicked, punched, or otherwise hurt by someone within the past year?” with yes/no option. 
Two questions assessed perceived safety by asking, “Do you feel safe in your current 
relationship?” and “Is there a partner from a previous relationship who is making you feel 
unsafe now?” with yes/no options. Three studies have assessed the sensitivity and 
specificity of the PVS (sensitivity, 35%-71%; specificity, 80%-94%) (Feldhaus et al., 
1997; Mills, Avegno & Haydel, 2006; MacMillan et al., 2009), and although it has 
demonstrated a wide range of sensitivity, it serves as a brief screen for identifying partner 
violence in the primary care setting. 
Data Analysis Plan 
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Statistical analyses were performed with SPSS version 24 (SPSS Inc., Chicago, 
IL, USA).  First, descriptive statistics were run for demographic data including gender, 
age, race, and ethnicity. Next, two study hypotheses were tested using univariate logistic 
regression for race and socioeconomic status, with insurance status, employment and 
education level serving as proxies for SES. For race, it was hypothesized that non-white 
ethnic minorities would be less likely to participate compared to white individuals. For 
socioeconomic status, it was hypothesized that individuals of lower socioeconomic status 
would be less likely to participate compared to those of a higher socioeconomic status 
Univariate logistic regression was also used to identify other correlates of study 
participation, sampling from such domains as alcohol and smoking, other drug use, 
family history of substance use, medical conditions, sleep, health behaviors, and other 
risk factors, including physical violence in the past year, feeling unsafe in current 
relationships, and drug use in current living environments. Significance was set at 0.05 
for all univariate analyses; however, any variables reaching a significance level of <0.2, 
along with basic demographic variables, were subsequently included in a multivariate 
logistic regression model to examine their effect in combination. When multiple items 
from the same domain reached significance, only one predictor was selected for inclusion 
in the multivariate analysis to avoid issues of multicollinearity. A multivariate logistic 
regression model, with backward elimination, was used to identify the most parsimonious 
model of predictors of research participation. The final model was achieved by 
eliminating covariates, one by one, that were not significant at the 0.05 level. The 
Hossmer Lemeshow test was used to check goodness-of-fit of the logistic regression, as 
well as the R-squared value to determine how much of the variance in research 
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participation was explained by the model. Given the computer directed nature of the 
survey; rates of missing data were very low. The data was treated as is, with any case 
with missing values excluded from the analyses.   
Results 
 Demographics. Demographic characteristics of consenters and non-consenters 
are summarized in Table 2, with variables eligible for inclusion in the multivariate 
analysis shown in italics. The first hypothesis that non-white ethnic minorities would be 
less likely to participate compared to white individuals was not supported.  The two 
groups did not significantly differ in race; approximately three-fourths of both consenters 
and non-consenters were African American (77% and 75%, respectively), 2(1, N = 
1,338) = 6.37, p = 0.59. The second hypothesis, that individuals of lower socioeconomic 
status would be less likely to participate compared to those of higher socioeconomic 
status, was also not supported. The two groups endorsed similar levels of educational 
attainment, with nearly one-third of non-consenters endorsing less than high school and 
26% of consenters, 2(2, N = 1,023) = 5.00, p = 0.08. While the two groups did differ on 
both employment and insurance status, both differences were not in the hypothesized 
direction. Instead, individuals of lower socioeconomic status were more likely to consent, 
and over half of consenters were unemployed (51%) as compared to 41% of non-
consenters, 2(5, N = 1,047) = 19.90, p = .001. For health insurance, while nearly twice 
as many non-consenters reported private insurance (11%) as consenters (6%), three-
fourths of consenters as compared to two-thirds of non-consenters reported the Virginia 
Coordinated Care Program (VCC), a program providing access to affordable health care 
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for uninsured individuals in Richmond (71% and 64%, respectively), 2(4, N = 1,047) = 
15.39, p = 0.009.   
 When other demographic variables were examined, consenters and non-
consenters did not differ on age or gender. Both groups were in their mid-40’s, 45.3 (SD 
= 10.8) and 45.1 (SD = 11.7) years, respectively, t (1336) = .26, p = 0.79, and over one-
third of both groups were male (39% of consenters and 41% of non-consenters), 2(1, N 
= 1,338) = .21, p = 0.66. The two groups did differ on marital status; with over half of 
non-consenters (51%) compared to 45% of consenters classified as single, 2(4, N = 
1,046) = 9.72, p = 0.04. 
Table 2. 
 
Demographic Characteristics of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
Age (years) 45.3 (10.8) 45.1 (11.7) 0.79 
Gender (% Male) 39% (281) 41% (254) 0.66 
Race   0.59 
    Black 77% (547) 75% (466)  
    White 19% (136) 20% (127)  
    Other 4% (30) 5% (32)  
Education   0.08 
    Less than high school 26% (139) 30% (143)  
    Grade 12 or GED 39% (212) 41% (193)  
  Some college and beyond 36% (195) 30% (141)  
Employment Status   0.001* 
   Full Time 11% (63) 18% (88)  
   Part Time 14% (77) 16% (76)  
   On disability 18% (103) 16% (78)  
   Unemployed 51% (284) 41% (200)  
   Retired 3% (17) 6% (28)  
   Student 3% (16) 4% (17)  
Health Insurance   0.009* 
   Private Insurance 6% (33) 11% (53)  
   VCC 71% (396) 64% (310)  
   Medicare 8% (44) 8% (37)  
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   Medicaid 10% (57) 9% (44)  
   Uninsured 5% (30) 9% (42)  
Marital Status   0.04* 
   Single 45% (250) 51% (246)  
   In a relationship 18% (100) 16% (79)  
   Married 13% (72) 15% (74)  
   Divorced 21% (119) 15% (71)  
   Widowed 3% (19) 3% (16)  
 
 Alcohol and Smoking.  The alcohol and tobacco use characteristics of the two 
groups are summarized in Table 3.  Consenters and non-consenters did not differ on a 
measure of tobacco use, with over three-fourths of consenters (79%) and 81% of non-
consenters having ever smoked in their lifetime, 2(1, N = 1,335) = 0.78, p = 0.38.  
Nearly two-thirds of each group were current smokers (60% consenters and 61% non-
consenters), 2(1, N = 1,338) = 1.91, p = 0.39.   
For alcohol, the two groups differed only on binge drinking, with 71% of 
consenters reporting at least one recent binge episode compared to 78% of non-
consenters, 2(1, N = 1,336) = 8.79, p = 0.003.  When males and females were examined 
separately, however, this difference was found only for males, (83% and 72%, 
respectively), 2(1, N = 535) 9.48, p = 0.002, and not females. No differences were found 
in prevalence of alcohol problems by CAGE (males) or T-ACE (females) screening tools.  
Table 3. 
 
Alcohol and Smoking of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
Tobacco Use    
   Ever Smoked (Lifetime) 79% (564) 81% (507) 0.38 
   Current Smoker 59% (422) 61% (384) 0.39 
Alcohol Use    
Binge Drinking (Past 30 days)    
     Overall 71% (503) 78% (484) 0.003 
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     Males 72% (202/281) 83% (211/254) 0.002 
     Females 70% (301/432) 73% (272/371) 0.21 
Positive Alcohol Screen    
     Overall 50% (353) 46% (286) 0.18 
     Men CAGE 41% (116/281) 39% (100/254) 0.65 
     Women T-ACE 56% (237/432) 44% (186/371) 0.19 
  
Recreational/Illicit Use and Problems.  Recreational and illicit drug use for the 
two groups are summarized in Table 4. Consenters were more likely to report recent 
recreational drug use (past 30 days) than non-consenters (36% and 26%, respectively), 
2(1, N = 1,338) = 16.83, p < 0.001.  Similarly, consenters were more likely to screen 
CAGE positive for drugs than non-consenters (29% and 17%, respectively), 2(1, N = 
1,337) = 26.51, p < 0.001.  Further, consenters reported using recreational drugs more 
days in the past month (M = 5.09, SD = 9.71), t (1330) = 3.19, p = 0.001, as well per 
week compared to non-consenters (M = 1.39, SD = 2.35), t (1336) = 3.11, p = 0.002.   
Prescription Drug Misuse. Prescription drug misuse rates and characteristics are 
also shown in Table 4, with consenters more likely to endorse recent prescription drug 
misuse than non-consenters (27% and 17%, respectively), 2(1, N = 1,337) = 17.78, p < 
0.001.  When specific symptoms of misuse were examined, consenters were more likely 
to endorse three of the four behaviors.  That is, they were more likely than non-
consenters to report taking more pills than prescribed, 2(1, N = 1,338) = 18.95, p < 
0.001, taking pills more often than prescribed, 2(1, N = 1,338) = 17.55, p < 0.001, and 
using someone else’s prescription, 2(1, N = 1,338) = 18.56, p < 0.001.   
Table 4. 
 
Recreational/Illicit Use and Problems of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
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Recreational Drug Use Past 30 days 36% (258) 26% (161) <0.001* 
Drug CAGE 29% (209) 17% (108) <0.001* 
Days (Past 30) Used Recreational Drugs 5.09 (9.71) 3.52 (8.33) <0.001* 
Days/Week (Past 30) Used Recreational 
Drugs 
1.39 (2.35) 1.01 (2.10) 0.002* 
Rx Drug Misuse (past 30 days) 27% (190) 17% (108) <0.001* 
   More pills than prescribed 16% (113) 10% (63) <0.001* 
   More often than prescribed 12% (85) 6% (40) <0.001* 
   Used someone else’s Rx 13% (91) 7% (42) <0.001* 
   Got Rx from more than one MD 2% (14) 2% (13) 0.88 
 
Family History of Alcohol and Drug Problems. Family history of alcohol or 
drug problems in first and second degree relatives are show in Table 5. A subset of group 
comparisons found consenters were more likely than non-consenters to report alcohol 
problems for their biological mother, 2(1, N = 1,336) = 7.88, p = 0.005, father, 2(1, N = 
1,336) = 4.57, p = 0.03, maternal and/or paternal grandmother, 2(1, N = 1,338) = 8.62, p 
= 0.003, and maternal and/or paternal grandfather, 2(1, N = 1,338) = 4.19, p = 0.04. 
Further, the two groups differed in parental density of alcohol problem patterns (no 
history, either parent, or both parents), with over half of non-consenters reporting no 
parental alcohol problems (54%) as compared to 46% of consenters, 2(2, N = 1,336) = 
9.72, p = 0.008.   
For other drug problems, the same group comparisons of consenters and non-
consenters yielded only one significant difference. That is, consenters were more likely to 
report drug problems in their biological fathers than non-consenters, 2(1, N = 1,337) = 
5.58, p = 0.02.   
Table 5. 
Family History of Alcohol and Drug Problems of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
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Alcohol Use    
Mother 21% (150) 15% (94) 0.005* 
Father 46% (331) 41% (253) 0.03* 
Grandmother 13% (91) 8% (49) 0.003* 
Grandfather 20% (140) 15% (96) 0.04* 
Parental Density   0.008* 
   No history 46% (330) 54% (337)  
   One parent 40% (285) 36% (225)  
   Both parents 14% (98) 10% (61)  
Drug Use    
Mother 10% (69) 9% (57) 0.74 
Father 15% (109) 11% (68) 0.02* 
Grandmother 2% (16) 1% (8) 0.19 
Grandfather 3% (19) 2% (12) 0.37 
 
 Medical Conditions.  Medical conditions for consenters and non-consenters are 
summarized in Table 6. Overall, there were no group differences, with the exception of 
hepatitis, which was endorsed by a higher percentage of consenters compared to non-
consenters (14% and 10%, respectively), 2(1, N = 1,338) = 3.84, p = 0.05. The two 
groups also did not differ in the number of medical diagnoses reported (M = 1.24, SD = 
1.28) for consenters compared to non-consenters (M = 1.13, SD = 1.06), t (1336) = 1.85, 
p = 0.06. 
Table 6. 
 
Medical Conditions of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
COPD 11% (81) 10% (63) 0.45 
Liver Disease 5% (32) 4% (24) 0.56 
Hepatitis 14% (98) 10% (64) 0.05* 
Heart Disease 12% (88) 10% (63) 0.19 
High Blood Pressure 55% (392) 51% (320) 0.17 
Pancreatitis 2% (17) 2% (12) 0.56 
High Cholesterol 26% (183) 26% (164) 0.81 
Mean Number of Conditions 1.24 (1.18) 1.14 (1.06) 0.06 
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 Sleep Behavior. Sleep behavior measures, including overall sleep quality ratings 
and medication use reports by consenters and non-consenters are summarized in Table 7. 
Quality of sleep ratings differed, with non-consenters more likely than consenters to 
report good/very good sleep (32% and 24%, respectively) and consenters more likely 
than non-consenters to report poor sleep quality (36% and 29%, respectively), 2(3, N = 
1,338) = 17.12, p = 0.002. Similarly, consenters were more likely to report trouble falling 
asleep, 2(1, N = 1,338) = 16.87, p = <0.001, and staying asleep, 2(1, N = 1,338) = 8.08, 
p = 0.02, than non-consenters. The same pattern was seen for sleep medication use, with 
nearly one-third of consenters using prescription medications for sleep (30%) as 
compared to one-fourth of non-consenters (25%), 2(3, N = 1,338) = 17.75, p = <0.001.   
Table 7. 
 
Sleep Behavior of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
Sleep Quality   0.002* 
    Poor 36% (257) 29% (179)  
    Fair 40% (288) 39% (244)  
    Good 18% (126) 25% (156)  
    Very Good 6% (42) 7% (44)  
Sleep Problems    
    Trouble Falling 72% (514) 62% (388) <0.001* 
    Trouble Staying 72% (516) 66% (410) 0.02* 
    Sleep Medications 49% (349) 38% (237) <0.001* 
Sleep Aids   <0.001* 
    None 51% (364) 62% (388)  
    Rx Only 30% (216) 25% (155)  
    Non-Rx Only 13% (89) 9% (59)  
    Both 6% (44) 4% (23)  
 
Mental Health-Related Conditions. Consenter and non-consenter self-reports of 
mental health problems and related conditions (e.g., migraines, chronic pain) are 
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summarized in Table 8. Group differences were found for all four conditions, with 
consenters more likely than non-consenters to endorse problems with anxiety, 2(1, N = 
1,338) = 10.61, p = 0.001, depression, 2(1, N = 1,338) = 19.17, p = <0.001, migraines, 
2(1, N = 1,338) = 4.62, p = 0.03, and chronic pain, 2(1, N = 1,338) = 6.37, p = 0.01. 
Mean number of conditions was also higher in consenters (M = 1.39, SD = 1.28) than 
non-consenters (M = 1.08, SD = 1.16), t (1336) = 4.65, p < 0.001 
Table 8. 
 
Mental Health-Related Conditions of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
Anxiety 39% (275) 30% (188) 0.001* 
Depression 48% (340) 36% (224) <0.001* 
Migraine 16% (111) 11% (72) 0.03* 
Chronic Pain 37% (267) 31% (193) 0.01* 
Mean Number of Conditions 1.39 (1.28) 1.08 (1.16) <0.001* 
 
 Health Behaviors. Physical health behaviors for the two patient groups are 
summarized in Table 9.  Overall, consenters and non-consenters reported similar amounts 
of physical activity, 2(3, N = 1,335) = 4.92, p = 0.18.  However, consenters indicated 
they spent a larger proportion of each day in sedentary activities compared to non-
consenters, 2(3, N = 1,334) = 10.88, p = 0.01.  Further, consenters were more likely to 
report having received a recommendation from a health professional to go on a diet 
compared to non-consenters, 2(1, N = 1,336) = 7.64, p =0.006.  
Table 9. 
 
Health Behaviors of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
Physical Activity (Past 30 Days)   0.18 
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    Rarely 24% (169) 25% (158)  
    Some Light/Moderate Not Every Week 23% (165) 27% (168)  
    Light/Moderate Every Week 36% (254) 33% (206)  
    30 minutes or more/day, 5+ days 18% (125) 15% (90)  
Average hours/day at desk, watching TV or 
playing video games 
  0.01* 
    0-2 hours 34% (244) 40% (247)  
    3-5 hours 26% (184) 29% (178)  
    6-8 hours 14% (102) 12% (77)  
    More than 8 26% (183) 19% (119)  
Health professional recommendation to go 
on a diet 
45% (319) 37% (233) 0.006* 
 
 Other Risk Factors.  Other risk factors, including physical violence in the past 
year, feeling unsafe in current relationships, and drug use in current living environment 
are summarized in Table 10.  There was no significant group difference in reports of 
feeling unsafe in current relationship, 6% of consenters compared to 7% of non-
consenters, 2(2, N = 1,337) = 3.07, p = 0.38.  However, consenters reported higher rates 
of physical violence, with 18% reporting violence in the past year compared to 13% of 
non-consenters, 2(1, N = 1,336) = 5.27, p = 0.02. Similarly, nearly twice as many 
consenters as non-consenters reported that a previous partner was making them feel 
unsafe, 2(1, N = 1,338) = 8.64, p = 0.003.  Lastly, twice as many consenters reported 
living with someone who currently had a drug problem compared to non-consenters, 
2(2, N = 1,338) = 15.33, p = <0.001. 
Table 10. 
 
Other Risk Factors of Consenters and Non-Consenters 
 
Variable 
Consenters 
(N=713) 
Non-Consenters 
(N=625) 
 
P value 
Unsafe Current 
Relationship 
6% (43) 7% (44) 0.38 
Physical Violence 
(past year) 
18% (129) 13% (84) 0.02* 
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Previous partner 
make feel unsafe 
9% (62) 5% (29) 0.003* 
Living with 
Someone with Drug 
Problem 
12% (82) 6% (39) <0.001* 
 
Multivariate Analysis 
 All of the variables included in the univariate analyses are summarized in Table 
11, with the variables selected for the multivariate italicized. The backward elimination 
included 30 iterations before arriving at the parsimonious model of predictors of research 
participation.  As shown in Table 12, older age, being unemployed or on disability, taking 
medications more often than prescribed, positive screen for drug problems (CAGE), 
having a grandmother with an alcohol problem, trouble falling asleep (past 30 days), 
health professional recommendation to go on a diet, and feeling unsafe due to a previous 
partner were all associated with consenting to participate in the SBIRT RCT.   
Participants with ≤ high school degree, as well as those who were employed or retired 
was associated with declining study participation. The model as a whole explained 
between 7.2% (Cox & Snell R Square) and 9.6% (Nagelkerke R Square) of the variance 
of subjects, and correctly classified 59.2% of cases. 
Table 11. 
Variables Included in Multivariate Logistic Regression 
Demographics  Substance Use Family History 
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Age 
Gender 
Race 
Education 
Employment  
Health Insurance 
Marital Status 
Tobacco Use (Lifetime and Current Status) 
Binge Drinking (Past 30 days) 
Positive Alcohol Screen (T-ACE & CAGE) 
Recreational Drug Use (Past 30 days) 
Positive Drug CAGE 
Days (Past 30) Rec. Drug Use 
Days/Week (Past 30) Rec. Drug Use 
Prescription Drug Misuse 
        More polls than prescribed 
        More often than prescribed 
        Used someone else’s Rx 
Alcohol     
    Mother 
    Father 
    Grandmother 
    Grandfather 
    Parental Density 
Drug Use 
    Mother 
    Father 
    Grandmother 
    Grandfather 
Sleep Behavior Physical Health Mental Health Other Risk Factors 
Sleep Quality 
Sleep Problems 
Sleep Aids 
COPD 
Liver Disease 
Hepatitis 
Heart Disease 
High Blood Pressure 
Pancreatitis 
High Cholesterol 
# of Conditions 
Physical Activity 
(Past 30 Days) 
Sedentary Activities 
Rec. to go on a diet 
Anxiety 
Depression 
Migraine 
Chronic Pain 
# of Conditions 
Unsafe Current 
Relationship 
Physical Violence  
(past year) 
Previous partner make 
feel unsafe 
Living with someone 
with a drug problem 
 
Table 12. 
Multivariate Logistic Regression 
 
 
Variable 
 
 
Estimate 
 
Standard 
Error 
 
 
P value 
 
Odds Ratio  
(95% CI) 
Age 0.013 0.007 0.045 1.01 (1.00, 1.03) 
Education   0.045  
    Less than high school -0.429 0.176 0.015 0.65 (0.46, 0.92) 
    Grade 12 or GED -0.268 0.158 0.089 0.77 (0.56, 1.04) 
Employment   0.016  
    Full Time -0.288 0.411 0.484 0.75 (0.34, 1.68) 
    Part Time -0.051 0.410 0.902 0.95 (0.43, 2.12) 
    On disability 0.222 0.416 0.593 1.25 (0.55, 2.82) 
    Retired -0.653 0.516 0.206 0.52 (0.19, 1.43) 
    Unemployed 0.258 0.391 0.510 1.29 (0.60, 2.79) 
% Positive Drug Cage 0.680 0.165 <0.001 1.97 (1.43, 2.73) 
Taking prescriptions 0.535 0.244 0.028 1.71 (1.06, 2.75) 
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more often than 
prescribed 
Grandmother had 
problem with alcohol 
0.501 0.228 .028 1.65 (1.06, 2.58) 
Trouble falling asleep in 
past 30 days 
0.292 0.141 0.039 1.34 (1.02, 1.77) 
Health professional 
recommendation to go 
on a diet 
0.293 0.135 0.030 1.34 (1.03, 1.75) 
Previous partner make 
feel unsafe 
0.626 0.291 0.031 1.87 (1.06, 3.31) 
 
Discussion 
 The purpose of the present study was to identify demographic and psychosocial 
variables associated with participation in a large primary care RCT of SBIRT targeting 
heavy/problem alcohol and/or drug use.  The study analyzed anonymous, computer-
administered health survey data through which eligible primary care patients for the RCT 
were identified. Using the N=1,338 patients who met RCT criteria and were invited to 
participate in the clinical trial, the present study compared those who consented to 
participate in the SBIRT RCT (N=713; consenters) with those that chose not to 
participate (N=625; non-consenters).  First, based on existing literature, two hypotheses 
about demographic variables associated with research participation, were tested. Second, 
univariate logistic regression was used to identify additional demographic and 
psychosocial correlates of consent to RCT participation. Third, variables significant in 
univariate analyses at the p <0.2 level were examined, using multivariate logistic 
regression to determine the most parsimonious model to predict patient consent to 
participate in a RCT targeting heavy/problem alcohol or drug use. 
Summary of Findings 
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 Present study findings did not support either of the two proposed hypotheses. 
Non-white ethnic minorities were not less likely to participate compared to white 
individuals.  Further, individuals of lower socioeconomic status were not less likely to 
consent compared to those of higher socioeconomic status. There was no significant 
difference in racial distribution across the two groups, and with the exception of 
educational attainment, group differences in SES-related variables were in a direction 
opposite to what was predicted, with consenters more likely to be unemployed and 
receiving medical services through the Virginia Coordinated Care Program (VCC) 
compared to non-consenters.  Additional univariate analyses of demographic variables 
found no differences in age, gender, or education between consenters and non-consenters. 
When psychosocial factors and physical concerns were examined, consenters 
endorsed both a larger number and more severe problems across multiple domains. 
Specifically, consenters were more likely to report sleep disturbance as well as symptoms 
of anxiety, depression, migraines, and chronic pain than non-consenters. They also spent 
more time each day in sedentary activities and were more likely to have received a 
recommendation from a health professional to go on a diet.  A larger proportion of 
consenters also resided with someone who had a drug problem, experienced an episode of 
physical violence (past year) and had a previous partner who was making them feel 
unsafe.  
Alcohol and other drug use measures were of particular interest, as they 
contributed to the criteria for RCT qualification. Consenters were more likely than non-
consenters to report recent and more frequent drug use, prescription drug misuse and 
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binge drinking.  Further, consenters were more likely to endorse a family history of 
substance use than non-consenters. 
 Using multivariate regression analysis, the most parsimonious model predicting 
consent to RCT participation included nine variables. Eight of these variables were 
associated with consent to RCT participation, including: older age, being unemployed or 
on disability, taking medications more often than prescribed, positive screen for drug 
problems (CAGE), having a grandmother with an alcohol problem, trouble falling asleep 
(past 30 days), health professional recommendation to go on a diet, and feeling unsafe 
due to a previous partner. In addition, the model found ≤ high school degree, as well as 
being employed or retired to be associated with the decision not to participate in the RCT. 
In addition, the model found ≤ high school degree, as well as being employed or retired to 
be associated with the decision not to participate in the RCT. The model as a whole 
explained between 7.2% (Cox & Snell R Square) and 9.6% (Nagelkerke R Square) of the 
variance, and correctly classified 59.2% of cases. 
Discussion of Findings 
 Hypothesis One. Present study findings do not support the first hypothesis. Non-
white ethnic minorities were not less likely to participate compared to white individuals. 
Historically, African Americans and other minority populations have participated in 
clinical trials far less when compared to whites due to mistrust of researchers and health 
care providers, as well as a lack of informational access to research opportunities (Durant 
et al., 2011; Anwuri et al., 2013; George et al., 2014). As an urban primary care clinic 
that treats many indigent persons in the catchment area, perhaps present study findings 
reflect a clinical network where African Americans feel more comfortable to participate 
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in research and one that educates and informs patients about diverse research 
opportunities. A review conducted by Wendler et al. (2005) suggested that the low rates 
of minority participation in research are not a reflection of minorities being less willing to 
participate, but instead is a result of structural barriers to accessing research opportunities 
and biased recruitment strategies (Wendler et al., 2005). The present study findings are 
consistent with this research, suggesting that when given the opportunity, ethnic 
minorities are willing to participate.  
Hypothesis Two. The present study also did not support the second hypothesis. 
Individuals of lower socioeconomic status were not less likely to consent compared to 
those of a higher socioeconomic status, and in most cases, the findings were contrary to 
what was predicted. That is, consenters were more likely to be unemployed or on 
disability than non-consenters. Similarly, consenters were more likely to be part of the 
Virginia Coordinated Care (VCC) program, while non-consenters were more likely to 
have private insurance. Previous research has suggested that low SES has a negative 
impact on clinical participation due to limited access to health care and research 
opportunities, as well as restrictions in their insurance coverage, with many relying on 
Medicare and Medicaid for health care coverage (Giuliano et al., 2000). Thus, present 
study findings might simply reflect the demographics of the clinic where it took place, 
which serves predominantly low-income, ethnic minorities within the VCC program. 
Such a sample increases homogeneity and restricts the range of core demographic 
variables. Study findings could also illustrate how individuals with private insurance are 
more likely to be employed, while those in VCC are more likely to be unemployed, 
affording them more time to participate in research. Lastly, the financial incentives for 
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study participants, while modest ($140 total), may also have contributed to the observed 
demographic pattern. 
 Mental Health-Related Conditions. The present study found consenters were 
more likely to endorse problems with anxiety, depression, migraines, and chronic pain 
than non-consenters. These findings are consistent with those reported for individuals 
enrolled in specialty-care substance abuse treatment programs. Specifically, the National 
Survey of Substance Abuse Treatment Services (NSSATS) found approximately 45% of 
Americans seeking substance use disorder treatment have been diagnosed with co-
occurring mental and substance use disorders (SAMHSA, 2015). Literature has suggested 
that individuals with comorbidities may be more likely to seek treatment. This is due in 
part to the Berkson’s bias, which states that persons with more than one disorder have an 
increased chance of being treated for either disorder, and in part to individuals being 
more likely to seek treatment due to the distressing symptoms of their comorbid mental 
health conditions (Hall & Farrell, 1997). Thus, individuals with comorbid conditions may 
also be more likely to consent to a clinical trial as a result of them being more aware that 
they are in need of help and motivated to seek services. 
If present study findings are valid, and RCT enrollees present with more severe 
mental health problems than the broader population of primary care patients with 
problem substance use, results have important implications for treatment. Patients with 
co-occurring mental health and substance use disorders frequently have less motivation to 
change, are harder to engage, drop out of long-term programs more easily, and make 
slow progress (Horsfall et al., 2009). Further, these individuals often require additional 
help with housing and employment services during their treatment. An interdisciplinary 
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approach to care is recommended in order to address the unique challenges associated 
with treating substance use in the presence of other conditions (Kelly, Daley & Douaihy, 
2012).  With this pattern, a treatment may appear less effective when provided to a severe 
patient sample, when that same treatment might be effective and clinically useful for a 
less severe and more representative clinic sample. This is of particular concern with the 
SBIRT treatment model, which is focused on prevention and early intervention and may 
be less effective in persons with psychiatric comorbidities. 
Sleep Behavior. Consistent with greater mental health comorbidity, consenters 
were more likely to report trouble falling asleep, poor sleep quality, and the use of sleep 
medications than non-consenters. The overlap between insomnia and substance use has 
been well established. Insomnia is not typically treated medically, and as a result, 
research has found that approximately 30% of insomniacs self-medicate with alcohol or 
over-the-counter (OTC) medications (Roehrs et al., 2002). While alcohol does initially 
promote sleep in low to moderate doses, its effects decrease with chronic use and it 
ultimately disrupts sleep-related physiology (Stein & Friedmann, 2006). Thus, research 
has also identified sleep disturbances as a consequence of alcohol use, with alcoholics 
experiencing prolonged sleep latency, decreased sleep time, decreased rapid eye 
movement sleep, decreased sleep efficiency, difficulty maintaining sleep, early 
awakening, and non-restorative sleep (Wallen et al., 2014). Consistent with psychiatric 
comorbidities, primary care patients have been found to be more likely to seek treatment 
for insomnia when in the presence of other medical conditions (Aikens & Rouse, 2005). 
Thus, individuals with sleep disturbances also may be more likely to consent to a clinical 
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trial as a result of them being better able to identify they are in need of services and 
motivated to seek treatment. 
This overlap between sleep and substance use also has important implications for 
treatment. Sleep disturbances have been found to independently increase the risk for 
relapse to alcohol (Wallen et al., 2014). Due to similar neurobiological and psychosocial 
processes in sleep and addictive behaviors, recent research suggests that this pattern may 
be true for a range of psychoactive substances, including, cocaine, amphetamines, and 
nicotine, supporting sleep as a universal risk factor for relapse (Brower & Perron, 2010). 
Disturbed sleep patterns can persist for months to years following the initiation of 
abstinence. As a result, adjuvant sleep treatments may be necessary, including both CBT-
I and pharmacologic approaches (Arnedt et al., 2007). Thus, treatments may not appear to 
be effective when tested without these additional components that address this heightened 
risk for relapse. 
 Substance Use. In order to qualify for the present study, participants had to 
screen positive for heavy/problem alcohol, illicit, and/or prescription drug misuse. Across 
these 3 domains, consenters were more likely to report recent illicit substance use than 
non-consenters. The National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC), which surveyed a representative sample of the non-institutionalized 
population in the United States, found that individuals who are drug dependent are 
approximately four times more likely to receive help than those who are dependent only 
on alcohol (Grella et al., 2015). The illegal status of drugs may underlie this distinction, 
where misuse of alcohol is more socially normative and drug dependence is more easily 
identified as problematic.  
  61 
 In addition, consenters reported using illicit drugs more frequently than non-
consenters, suggesting that the sample under investigation may also have a more severe 
substance use problem than the full population of interest. Similarly, consenters were 
more likely to report a family history of substance use than non-consenters. Research 
suggests that family history of substance use may be associated with an earlier age of 
onset, and in turn, greater severity of use (Johnson et al., 2000). This pattern may reflect 
that patients with more severe use may be better able to recognize that they are in need of 
treatment and therefore have more motivation to consent to an SBIRT trial. This pattern 
also has important implications for treatment. Although evidence for SBIRT is 
promising, there is less evidence in the literature for its efficacy among patients with very 
heavy use or dependence. A systematic review conducted by Saitz (2011) found that 
patients with heavy alcohol use or dependence were excluded from the majority of 
clinical trials. When they were included, the treatment approach showed no significant 
difference in alcohol severity. A similar review on the efficacy of SBIRT with drug use 
also demonstrated limited efficacy, suggesting that the treatment model also may not be 
effective when targeting other (non-alcohol) drugs of abuse (Saitz, 2014). Taken together, 
if individuals with more severe substance use are more likely to consent to participate, 
RCT outcomes may not generalize to less severe forms of use found among patients 
attending the clinic. 
Multivariate Analysis. The multivariate regression analysis identified the 
variables included in a parsimonious model of predictors of research participation. 
Specifically, the final model found that older age, unemployment, illicit substance use, 
prescription misuse, family history of alcohol use, sleep disturbances, receiving health 
  62 
professional recommendation to go on a diet, as well as more unstable living 
environments were all associated with research participation. Taken together, consenters 
reported experiencing a larger number of psychosocial and medical comorbidities than 
non-consenters. This pattern could be a result of these individuals being more likely to be 
in clinic for one of their concerns, providing easier access to screen them for eligibility 
and making the RCT visits more compatible with their schedule and time in the clinic. 
Further, these individuals may be able to more readily identify they are in need of 
services due to their comorbidities, as well as have more time to participate since they are 
unemployed. Lastly, this could be a result of non-consenters minimizing their problems 
and not providing an accurate reflection of their current health and functioning. 
While the multivariate model provides a profile of individuals more likely to 
consent to research participation, it is important to note that this model only accounted 
for between 7.2% (Cox & Snell R Square) and 9.6% (Nagelkerke R Square) of the 
variance of subjects.  While the clinical significance of these findings may appear 
limited, it is important to remember the present study was secondary analysis of existing 
data and survey items sampled broadly but with limited questions for each domain. Thus, 
present study results represent only the first step in a promising and important area of 
research with opportunities to further explore potential differences between those who do 
and do not consent to SBIRT research study participation.  
Study Implications and Applications 
 The present study provides benchmark data on sample representativeness in a 
clinical trial of SBIRT. The anonymous computer-based primary care screening survey 
afforded a unique opportunity to compare RCT participants and non-participants across a 
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wider array of variables than previously found in the literature. Overall, consenters had a 
larger number and more severe problems across the domains surveyed. This could be a 
result of these individuals being able to more readily identify that they are in need of 
treatment with more motivation to participate in the trial. Conversely, it could also be a 
reflection of non-consenters minimizing their problems with less willingness to provide 
an accurate depiction of their current health and functioning.   
 Demographic factors, such as being unemployed and having no health insurance 
were also associated with research participation. This pattern may illustrate that 
unemployed patients consented to the research because they were not working and 
therefore had more time available for the study. Alternatively, the relationships might be 
more complex, with mental health issues and substance use contributing to job loss and 
unemployment.  
While statistical differences were found between consenters and non-consenters, 
the final model accounted for only about 10% of the variance in research participation. 
However, the present study serves as the first step exploring potential differences 
between participants and non-participants, and given that the data across these broad 
domains accounted for variance in research participation, it affirms the need to explore 
these domains in greater detail in order to ensure the representativeness of SBIRT 
research. This is of particular importance given mixed results in SBIRT outcome studies 
targeting other drugs of abuse, with some showing positive findings (Madras et al., 
2009), and other reporting no differences between SBIRT and control condition (Saitz, 
2014). If clinical trials are conducted on more severe samples, the SBIRT intervention 
may be found to be ineffective, when in fact it could have great clinical utility for persons 
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with less severe use. Gaining a better understanding of the sample under investigation, 
and how their use compares to the population of interest, would ensure the findings are 
generalized appropriately. 
 In addition to the sample representativeness, it is also important to take note of the 
recruitment and consent process in the clinical trial. While many SBIRT studies do not 
report rates of informed consent, the present study rate (53%) was lower than others in 
the literature (e.g., Madras et al., 2009; Kaner et al., 2013), which could be a reflection of 
the overall study design. Participants completed the anonymous survey during their first 
appointment, and then if eligible, were asked to proceed to the baseline assessment. Thus, 
practical issues could have accounted for participants being unable or unwilling to make 
an additional time commitment beyond the initial screening phase.  In addition, research 
has suggested that the method in which patients are recruited could influence the 
characteristics of the obtained sample, as well as treatment effects (Winhusen et al., 
2012).  For instance, consenters were more likely to be unemployed and uninsured, 
suggesting that the access to services and financial incentives may be more effective with 
this patient population.  Further, more severe medical histories of consenters may have 
prompted them to seek services of any kind with greater motivation to enroll in the trial. 
Lastly, the stigma around substance use, particularly alcohol versus illicit substances, 
may also have played a role in willingness to participate. Gaining a better understanding 
of these factors could help tailor recruitment efforts to the target population and improve 
the representativeness of the sample. 
 Lastly, the present study provides important information about the characteristics 
of the patient population presenting in primary care clinics. Given that substance use 
  65 
services have historically been in specialized treatment centers, the present study 
provides a better understanding of the demographics, medical backgrounds, psychosocial 
characteristics, and substance use behaviors of the 85% of patients who traditionally may 
never present for substance abuse treatment services. These findings can serve to inform 
the implementation and tailoring of SBIRT to meet patient needs in various medical care 
settings.  
Study Strengths, Limitations, and Future Directions  
Strengths 
The present study had a number of important strengths.  First, whenever possible, 
Health Cheq used reliable and valid measures to assess for problems in each domain of 
interest.  Further, the format and delivery of the Health Cheq survey promoted patient 
anonymity and comfort.  Patients were told that the survey was a “Patient Health Check-
Up” with no mention of substance use, which may have increased patient willingness to 
complete the survey.  When a survey is presented as a measure of substance use, it can 
influence the patient’s decision to complete the survey, as well as their subsequent 
responses. The survey included many items that had nothing to do with substance use in 
an effort to mask the true purpose of the screener.  Peedy, the computer avatar, asked 
questions regarding other health behaviors such as exercise, eating habits, and sleep to 
reduce the stigma associated with the screener and allow patients to get comfortable 
using the computer before answering questions regarding their substance use.  In 
addition, the participant was informed that all of their responses would remain 
anonymous, which also served to promote patient comfort and limit fear of disclosing 
information on sensitive topics.  
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Second, while RCT eligibility had few exclusion criteria, promoting heterogeneity 
and sample representativeness, it also added to those who would be clinically eligible for 
and might benefit from SBIRT services. The limited exclusion criteria also made patients 
with comorbidities, polysubstance use, and different ethnic backgrounds eligible for the 
study, providing information across the spectrum of use and severity. This enabled the 
data to reflect the complexities that are typically seen in primary care. 
 Third, using Health Cheq as the initial screening tool offered a unique opportunity 
to collect data on this large pool of participants who often may not come to the attention 
of the research team.  Clinical trials rarely have any information on patients who decline 
research participation beyond basic demographics.  Health Cheq provided a rich dataset 
on the eligible pool of patients in order to examine any potential differences between 
consenters and non-consenters.    
Fourth, the use of the electronic screener provided a more comprehensive, 
reliable, and less biased approach to collecting data than interviews and ratings conducted 
in clinical practice (Trull, 2007).  Technology also offers increased privacy for 
participants, which may improve accuracy of responses when reporting on stigmatized 
health behaviors. In addition, Health Cheq used an animated avatar to ask questions and 
guide participants through the survey. The narrator is able to speak, move, and provide 
empathetic reflections (Pollick et al., 2015). This format is more engaging and less 
intimidating than traditional health screeners. Lastly, Health Cheq included branching 
logic that streamlined the screening tool and all answers were recorded by simply tapping 
responses from a list. This helped cut down on the overall time to complete the screener 
and limited missing data. 
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Limitations 
Despite these strengths, some limitations were also present. First, the Health Cheq 
survey relied on retrospective, self-report information.  Although self-reports are used 
extensively throughout clinical research, they are subject to biases that are difficult to 
control even under the best of circumstances.  This is particularly true when respondents 
are asked to report on stigmatized behaviors such as substance use and HIV risk 
behaviors (Harrison, 1995; Smith et al., 2008). With Health Cheq, while the primary 
purpose of the survey was to identify those at risk for heavy/problem substance use, this 
was not made explicit during Health Cheq recruitment. Instead, it was described as an 
anonymous general health and risk behaviors survey. This was done in part, to minimize 
social desirability. Therefore the survey included questions that did not pertain to 
substance use. Research efforts to mask the primary purpose of the screener, however, 
may have become less successful over time, as the clinic became aware of an ongoing 
RCT that involved substance use. Patients could converse in the waiting area and this 
may have influenced how they responded to the substance-related survey items. 
However, the fact that the survey was anonymous may have mitigated these factors and 
promoted patient comfort in answering items honestly. 
 Second, the sample was recruited from an urban clinic that serves predominately 
low-income, ethnic minorities.  The homogeneity of patients served in this setting limited 
the range for several demographic variables and may explain why study findings did not 
resemble those previously reported for patient demographics. A more heterogeneous 
sample may have revealed more information about the characteristics associated with 
research participation and improved the generalizability of study findings.  
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Third, the univariate analyses required a number of comparisons across groups, 
which increased the probability of a committing a Type I error.  The larger the number of 
tests, the easier it is to detect an effect when in fact there is none (Abdi, 2007).  However, 
the exploratory nature of the study necessitated a large number of comparisons in order to 
fully explore what domains may be of interest.  
Lastly, the study did not specify whether marijuana use was for medicinal 
purposes, and instead classified other drugs as recreational/illicit or prescription, with 
marijuana categorized under recreational/illicit. Therefore, this could have resulted in a 
mischaracterization of reported substance use and skewed the obtained results. Further, 
the limited exclusion criteria enabled polysubstance use to be included in the study, with 
drug CAGE questions asked broadly across all substances (excluding alcohol), which 
often made it difficult to parse out the type of use and associated psychosocial and 
medical issues. 
Future Directions 
This present study serves as an initial investigation into characteristics associated 
with participation in a clinical trial of SBIRT.  Using secondary data analyses, the study 
was limited by variables in the Health Cheq survey. Thus, future research should build 
upon these findings and include more detailed screeners of potential participants. Gaining 
a better understanding of the eligible pool of participants will ensure the obtained sample 
is representative and the findings are generalizable to the population of interest.   
Efforts should also be made to follow patients throughout clinical trials to see 
how differences in participant characteristics may influence RCT outcomes. For instance, 
gaining a better understanding of how differences in substance use severity, family 
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history, risk behaviors, etc. are manifested in treatment outcomes provides information on 
how these differences are influencing clinical research and generalizability of study 
findings. Gaining a better understanding of these underlying factors would offer 
opportunities to tailor interventions to the specific needs of different patient populations. 
Future research should also broaden this work to clinics that serve a broader 
spectrum of patients in order to see how these findings may vary with different 
socioeconomic and cultural backgrounds. This may need to be accomplished through 
multisite trials in order to obtain the full continuum of patients presenting in primary 
care. This research would provide important information on primary care patients as a 
whole and provide insight into how findings may vary across patient populations and 
clinical settings.  
Lastly, future research should incorporate a measure of motivation when 
screening participants for eligibility in order to see how motivation may influence their 
willingness to participate. Further, efforts should be made to understand how motivation 
may influence treatment outcomes. This would provide valuable information on how 
motivation may correlate with specific conditions, as well as how this in turn may 
influence study participation and findings.  
Conclusion 
In summary, the present study offered a unique opportunity to compare RCT 
consenters and non-consenters across a wider array of variables than previously found in 
the literature. Overall, consenters reported a larger number and more severe problems 
across the many domains surveyed. These findings could have important implications for 
treatment outcomes, as well as the generalizability of study findings. The present study 
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serves as a preliminary analysis of predictors of research participation, and highlights the 
need to explore these factors in future research in order to ensure the representativeness 
of SBIRT research. 
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